{"add": {"doc": {"field": [{"@name": "docid", "#text": "BR-TU.18624"}, {"@name": "filename", "#text": "25634_000873023.pdf"}, {"@name": "filetype", "#text": "PDF"}, {"@name": "text", "#text": "UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL \u2013 UFRGS \n\nFACULDADE DE MEDICINA \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM MEDICINA: CI\u00caNCIAS M\u00c9DICAS \n\n \n\n \n\n \n\n \n\nAVALIA\u00c7\u00c3O DOS \u00cdNDICES DE DNA DANIFICADO EM USU\u00c1RIOS DE CRACK \n\n \n\n \n\n \n\nThiago Aley Brites de Freitas \n\n \n\n \n\n \n\nOrientadora: Dr\na\n Sandra Leistner Segal \n\n \n\n \n\n \n\n \n\nPorto Alegre, Dezembro de 2012 \n\n \n\n \n\n \n\nDISSERTA\u00c7\u00c3O DE MESTRADO \n\n \n\nUNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL \u2013 P\u00f3s-Gradua\u00e7\u00e3o em \nMedicina: Ci\u00eancias M\u00e9dicas. Faculdade de Medicina \u2013 Rua Ramiro Barcellos, 2400, \n\n2\u00ba andar. 90035-003. Fone: #55 51 33085605. Fax: #55 51 33085606. E-mail: \n\nppgcm@ufrgs.br  \n\nmailto:ppgcm@ufrgs.br\n\n\n 2 \n\nUNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL \u2013 UFRGS \n\nFACULDADE DE MEDICINA \n\nPROGRAMA DE P\u00d3S-GRADUA\u00c7\u00c3O EM MEDICINA: CI\u00caNCIAS M\u00c9DICAS \n\n \n\n \n\n \n\n \n\nAVALIA\u00c7\u00c3O DOS \u00cdNDICES DE DNA DANIFICADO EM USU\u00c1RIOS DE CRACK \n\n \n\n \n\nThiago Aley Brites de Freitas \n\n \n\n \n\n \n\nOrientadora: Prof\u00aa. Dra. Sandra Leistner Segal \n\n \n\n \n\n \n\nDisserta\u00e7\u00e3o de Mestrado \n\n \n\nA apresenta\u00e7\u00e3o desta disserta\u00e7\u00e3o \n\u00e9 exig\u00eancia do Programa de P\u00f3s- \nGradua\u00e7\u00e3o em Medicina: Ci\u00eancias \nM\u00e9dicas, da Universidade Federal \ndo Rio Grande do Sul, para \nobten\u00e7\u00e3o do t\u00edtulo de Mestre. \n\n \n\n \n\n \n\n \n\nPorto Alegre, Dezembro de 2012 \n\n \n\n\n\n 3 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nDedico este trabalho a todas as pessoas \n\nque fizeram parte dele, tornando-o \n\nposs\u00edvel. \n\n \n\n\n\n 4 \n\nAgradecimentos \n\nA Deus por proporcionar-me a vida, e o suporte para viv\u00ea-la \n\n\u00c0 Dra. Sandra Leistner Segal pela disponibilidade da orienta\u00e7\u00e3o, pelo apoio e solicitude \n\nno decorrer do trabalho, oferecendo mais que uma oportunidade, a realiza\u00e7\u00e3o de um \n\nsonho. \n\nAo Dr. Sharbel Weidner Maluf por todas as oportunidades oferecidas at\u00e9 ent\u00e3o, que \n\ncome\u00e7aram ainda no per\u00edodo de gradua\u00e7\u00e3o, pela presen\u00e7a, dedica\u00e7\u00e3o, ensinamentos, \n\npaci\u00eancia e principalmente pela amizade. \n\n\u00c0 Doutoranda e querida amiga Isabel Cristina Bandeira, que teve fundamental \n\nparticipa\u00e7\u00e3o na elabora\u00e7\u00e3o desta disserta\u00e7\u00e3o, apoiando, incentivando.  \n\n\u00c0 aluna Gisele Gomes de Andrade, por todo aux\u00edlio prestado na execu\u00e7\u00e3o das \n\natividades de bancada. \n\n\u00c0 Ms. Roberta Passos Palazzo, pelos ensinamentos das t\u00e9cnicas e todo o auxilio \n\nprestado e principalmente pela amizade. \n\nAo estat\u00edstico Luciano Guimar\u00e3es, por toda a ajuda oferecida. \n\n\u00c0 minha fam\u00edlia, pelo incentivo constante, preocupa\u00e7\u00e3o e carinho. \n\nAos meus amigos dos laborat\u00f3rios de Biologia Molecular e Citogen\u00e9tica Cl\u00e1ssica por \n\ntoda a ajuda relacionada a essa pesquisa. A todos os funcion\u00e1rios e estudantes do \n\nServi\u00e7o de Gen\u00e9tica M\u00e9dica. \n\nAo Programa de P\u00f3s-Gradua\u00e7\u00e3o em Ci\u00eancias M\u00e9dicas da Universidade Federal do Rio \n\nGrande do Sul, pela disposi\u00e7\u00e3o a ajudar e esclarecer d\u00favidas que surgiram durante \n\nessa caminhada, procurando sempre auxiliar para que tudo fosse resolvido da forma \n\nmais eficiente poss\u00edvel. \n\n \n\n\n\n 5 \n\nAos participantes do estudo, pela valorosa contribui\u00e7\u00e3o, n\u00e3o apenas pela \n\ndisponibiliza\u00e7\u00e3o do material gen\u00e9tico, mas pela paci\u00eancia em responder aos \n\nquestion\u00e1rios, sempre de forma interessada e amistosa. \n\n\u00c0 minha noiva Camila Pereira Andrade pela compreens\u00e3o e paci\u00eancia nos momentos \n\nde aus\u00eancia. \n\nA todos os meus amigos, por fazerem parte.   \n\n\u00c0s institui\u00e7\u00f5es de fomento a pesquisa: CNPq, Fapergs e Fipe-HCPA, pelo valioso apoio \n\nfinanceiro. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 6 \n\nLista de abreviaturas e siglas \n\nCBMN  cytokinesis-blocked micronucleus \n\nMN  micron\u00facleo \n\nNPB  nucleoplasmic bridges \n\nBUD   nuclear bud \n\nSCGE  single-cell gel electrophoresis \n\nDNA  \u00e1cido desoxirribonucl\u00e9ico  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 7 \n\n \n\nLista de figuras \n\n \n\nFigura 1: Ilustra\u00e7\u00e3o das etapas da t\u00e9cnica do cometa..................................................19 \n\nFigura 2: Linf\u00f3citos processados pela t\u00e9cnica do cometa.............................................20 \n\nFigura 3: Linf\u00f3citos processados pela t\u00e9cnica de micron\u00facleos....................................22 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 8 \n\nSUM\u00c1RIO \n\nRESUMO....................................................................................................... 9 \n\nABSTRACT.................................................................................................... 11 \n\nINTRODU\u00c7\u00c3O.............................................................................................. 13 \n\nREVIS\u00c3O DA LITERATURA........................................................................ 15 \n\n1. Caracteriza\u00e7\u00e3o e Hist\u00f3rico......................................................................... 15 \n\n2. Dano de DNA............................................................................................. 17 \n\n2.1. T\u00e9cnicas para avalia\u00e7\u00e3o de dano de DNA.............................................. 19 \n\n2.1.1.  Ensaio Cometa................................................................................... 19 \n\n2.1.2. Teste de Micron\u00facleo........................................................................... 20 \n\n4. OBJETIVOS............................................................................................... 23 \n\n4.1. Objetivo Principal.................................................................................... 23 \n\n4.2. Objetivos Secund\u00e1rios............................................................................ 23 \n\n5. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS.......................................................... 24 \n\n6. MANUSCRITO........................................................................................... 31 \n\n7. CONSIDERA\u00c7\u00d5ES FINAIS E PERSPECTIVAS....................................... 51 \n\n8. ANEXOS.................................................................................................... 53 \n\n8.1. Termo de Consentimento Livre e Esclarecido (grupo teste)................... 53 \n\n8.2. Termo de Consentimento Livre e Esclarecido (grupo controle).............. 55 \n\n8.3. Question\u00e1rio de Sa\u00fade Pessoal............................................................. 57 \n\n \n\n \n\n \n\n \n\n\n\n 9 \n\nRESUMO  \n\nO crack \u00e9 um subproduto da coca\u00edna obtido a partir da pasta de coca acrescida \n\ndo bicarbonato de s\u00f3dio, sendo comercializado na forma de pequenas pedras porosas. \n\nNo Brasil, o consumo de crack tem sido alvo de grande preocupa\u00e7\u00e3o devido \n\nsua expressiva expans\u00e3o em v\u00e1rias regi\u00f5es, sendo que o aumento da preval\u00eancia do \n\nseu consumo vem sendo amplamente documentado nos \u00faltimos anos. A depend\u00eancia \n\nde crack \u00e9 a causa mais prevalente de interna\u00e7\u00e3o por uso de coca\u00edna. H\u00e1 uma \n\nnecessidade imediata de estudos que se direcionem para esta popula\u00e7\u00e3o. \n\nA presente pesquisa pretende demonstrar evid\u00eancias capazes de contribuir \n\npara o entendimento dos mecanismos envolvidos na a\u00e7\u00e3o do psicotr\u00f3pico crack sobre \n\no DNA, bem como oferecer dados que auxiliem no desenvolvimento de tratamentos \n\npara pacientes usu\u00e1rios abusivos desta droga. \n\nEste estudo teve como objetivo avaliar o dano ao DNA e a capacidade de \n\nreparo, em 31 indiv\u00edduos usu\u00e1rios ativos de crack, relacionando-os com um grupo \n\ncontrole com 40 participantes. O trabalho foi desenvolvido atrav\u00e9s de volunt\u00e1rios rec\u00e9m \n\ninternados na Cl\u00ednica Marcelo Campos em S\u00e3o Leopoldo. Foram coletadas amostras \n\nem tr\u00eas momentos (interna\u00e7\u00e3o, 48h ap\u00f3s e ao t\u00e9rmino do tratamento) e submetidas \u00e0s \n\nt\u00e9cnicas de micron\u00facleo e cometa. Dentre os resultados desta avalia\u00e7\u00e3o, foram \n\nevidenciados \u00edndices de dano significativamente diferentes entre os grupos nas \n\nt\u00e9cnicas de micron\u00facleos e cometa, e entre os per\u00edodos de coleta na t\u00e9cnica de \n\ncometa. Os valores obtidos para o \u00edndice de dano de DNA da t\u00e9cnica do cometa nos \n\ntr\u00eas momentos de avalia\u00e7\u00e3o revelaram uma diminui\u00e7\u00e3o estatisticamente significativa \n\napenas ap\u00f3s o t\u00e9rmino do tratamento. \n\n\n\n 10 \n\n \n \n\n  \n\nEm rela\u00e7\u00e3o \u00e0 utiliza\u00e7\u00e3o concomitante de outras subst\u00e2ncias, o consumo de \n\ntabaco ocorreu em 68% dos indiv\u00edduos, maconha em 71% e coca\u00edna em 32%, sendo \n\nque 19% faziam uso concomitante de todas as drogas mencionadas. Houve correla\u00e7\u00e3o \n\ncom o tempo de uso do tabaco e o \u00edndice de dano (P=0,043), MN (P=0,017) e NBP \n\n(P=0,023) em determinados momentos. O consumo de \u00e1lcool ocorreu em 61,29% dos \n\nparticipantes, n\u00e3o havendo correla\u00e7\u00e3o estatisticamente significativa com os marcadores \n\nde dano. A idade e o tempo de utiliza\u00e7\u00e3o do crack n\u00e3o apresentaram associa\u00e7\u00e3o ao \n\n\u00edndice de dano. Houve associa\u00e7\u00e3o significativa entre o consumo de chimarr\u00e3o (Ilex \n\nparaguaiensis) e MN (P= 0,045). Estudos associando o crack com dano ao DNA s\u00e3o, \n\nainda, escassos. Este trabalho buscou acrescentar informa\u00e7\u00f5es quanto ao potencial \n\ndanoso desta subst\u00e2ncia. \n\nPalavras-chave: Usu\u00e1rios de Crack, Dano de DNA, Ensaio Cometa, T\u00e9cnica de \n\nMicron\u00facleos. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 11 \n\nABSTRACT \n\nCrack is a by-product of cocaine resulting from the addition of sodium \n\nbicarbonate to cocaine base paste, being sold in the form of small, porous rocks.  \n\nIn Brazil, the consumption of crack has been the subject of great concern due to \n\nits significant expansion in various regions, thus the increasing prevalence of drug use \n\nhas been documented in recent years. The dependence of crack is the most prevalent \n\ncause of hospitalization due to cocaine use, supporting an immediate need for studies \n\nto target this population. \n\nThis research aims to demonstrate evidence that can contribute to the \n\nunderstanding of the mechanisms involved in the action of psychotropic Crack on DNA, \n\nas well as provide data to assist in development of treatments for patients who are drug \n\nabusers. \n\nThis study aimed to assess the damage and DNA repair capacity in 31 \n\nindividuals who are active users of crack, comparing them to a control group of 40 \n\nparticipants. The study was conducted by volunteers newly admitted to the Clinic \n\nMarcelo Campos in S\u00e3o Leopoldo. Samples were collected at three time points (at \n\nadmission, 48 hours latter and at the end of treatment) and subjected to the comet and \n\nmicronucleus techniques. Among the results of this assessment damage indices were \n\nevident and significantly different between groups in the comet and micronucleus \n\ntechniques, and between sampling periods for the comet technique. \n\nThe values obtained for the rate of DNA damage in the comet technique in all \n\nthree time points revealed a statistically significant decrease only after the end of \n\ntreatment. Regarding the concomitant use of other substances, no significant \n\nassociation was found with the results. Tobacco consumption occurred in 68% of \n\n\n\n 12 \n\nsubjects, marijuana in 71% and cocaine in 32%, being 19% users of all drugs \n\nmentioned. There was a correlation over time of tobacco use and the damage index (P \n\n= 0.043), MN (P = 0.017) and NBP (P = 0.023) at certain time points.. Alcohol \n\nconsumption occurred in 61.29% of the participants, there was no statistically significant \n\ncorrelation with markers of damage.The age and duration of use were not associated to \n\nthe crack damage index. There was a significant association between the consumption \n\nof yerba mate (Ilex paraguaiensis) and MN. (P = 0.045). Studies associating the crack \n\nwith DNA damage are still scarce. This study brings additional information about the \n\npotential harmful of substance. \n\nKeywords: Crack users, DNA damage, Comet Assay, Micronucleus test \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 13 \n\nINTRODU\u00c7\u00c3O \n\nO crack \u00e9 uma droga em r\u00e1pido aumento de consumo em todo o mundo; \u00e9 \n\nconsiderada extremamente nociva e com alto poder para causar depend\u00eancia \n\nrapidamente. Inicialmente consumida por camadas mais pobres da popula\u00e7\u00e3o, \n\natualmente, tem seu uso difundido nas classes m\u00e9dia e alta. Como ainda \u00e9 uma \n\nsubst\u00e2ncia relativamente recente, seus potenciais danos s\u00e3o muito descritos em \n\ntermos de sa\u00fade geral do indiv\u00edduo e impacto socioecon\u00f4mico. Contudo, pouco \u00e9 \n\nsabido de potenciais danos do crack a aspectos mais espec\u00edficos, em n\u00edvel celular.   \n\nAssim, o presente projeto prop\u00f5e-se a estudar os poss\u00edveis n\u00edveis de dano ao \n\nDNA nos leuc\u00f3citos de usu\u00e1rios de crack e acompanhar esses n\u00edveis durante o \n\ntratamento em uma cl\u00ednica de reabilita\u00e7\u00e3o. Trata-se de um estudo original, ainda n\u00e3o \n\nrealizado, nesta popula\u00e7\u00e3o estudada. \n\n Este estudo consiste em uma avalia\u00e7\u00e3o das altera\u00e7\u00f5es no material gen\u00e9tico \n\n(DNA) de cada participante. Estas altera\u00e7\u00f5es ocorrem normalmente nas c\u00e9lulas em \n\nn\u00edveis bastante baixos e s\u00e3o apontadas como respons\u00e1veis, entre outros efeitos, pelos \n\nprocessos de envelhecimento.   Segundo KESSLER, (2008), fica evidente tanto para a \n\ncomunidade cient\u00edfica quanto para a leiga brasileira que o crack \u00e9 uma droga de grande \n\nimpacto, representando mais do que um dano espec\u00edfico ao organismo do individuo. No \n\nmomento atual, uma das quest\u00f5es centrais discutidas no pa\u00eds \u00e9 a preval\u00eancia de seu \n\nconsumo. Os principais estudos nessa \u00e1rea foram realizados pelo Centro Brasileiro de \n\nInforma\u00e7\u00f5es sobre Drogas Psicotr\u00f3picas, sendo que apenas nos \u00faltimos levantamentos \n\no uso de crack foi relacionado, corroborando estudos pontuais que sugerem haver \n\nrealmente um aumento no seu consumo.   \n\n\n\n 14 \n\nA realiza\u00e7\u00e3o deste estudo permitir\u00e1 conhecer se o DNA de usu\u00e1rios tem mais \n\naltera\u00e7\u00f5es do que a m\u00e9dia da popula\u00e7\u00e3o, podendo estes resultados servir como base \n\npara a preven\u00e7\u00e3o de efeitos danosos sobre a sa\u00fade. \n\n \n\n \n\n\n\n 15 \n\nREVIS\u00c3O DA LITERATURA \n\n1 Caracteriza\u00e7\u00e3o e Hist\u00f3rico \n\nA coca\u00edna \u00e9 um estimulante do sistema nervoso central, extra\u00edda das folhas da \n\nplanta Erythroxylon coca (Ribeiro-Ara\u00fajo et al.,1998 apud Duailibi et al., 2008).  Pode \n\nser consumida sob a forma de cloridrato de coca\u00edna, um sal hidrossol\u00favel, de uso \n\naspirado ou injetado. H\u00e1 ainda as apresenta\u00e7\u00f5es alcalinas, vol\u00e1teis a baixas \n\ntemperaturas, que podem ser fumadas em \u201ccachimbos\u201d, como \u00e9 o caso do crack, da \n\nmerla e da pasta b\u00e1sica da coca\u00edna (Benowitz, 1992). O crack \u00e9 um subproduto da \n\ncoca\u00edna que \u00e9 obtido a partir da pasta de coca acrescida do bicarbonato de s\u00f3dio, \n\nsendo comercializado na forma de pequenas pedras porosas (Nassif Filho, 1999). \n\nNa transi\u00e7\u00e3o para os anos 80, a coca\u00edna entrou num contexto no qual se \n\ntornara a principal atra\u00e7\u00e3o. Menos de dez anos depois, o consumo do crack j\u00e1 era \n\nmaior do que o da coca\u00edna. Essa apresenta\u00e7\u00e3o, ao contr\u00e1rio da anterior, disseminou-se \n\nespecialmente em locais socialmente exclu\u00eddos, tendo os meninos de rua e os usu\u00e1rios \n\nde drogas injet\u00e1veis seus principais adeptos (Jonnes, 1996; Nappo et. al, 1994). O \n\ncrack surgiu no Peru na d\u00e9cada de 1970, mas veio para os Estados Unidos em meados \n\nde 1985 (Washton et al, 1986), no Canad\u00e1 em 1986 (Smart, 1988) e nos pa\u00edses \n\neuropeus, um pouco mais tarde (Strang et al., 1990). Desta forma, a partir 1987, o uso \n\nda coca\u00edna vem aumentando em todo o mundo, principalmente na forma de pedra, o \n\ncrack (Das, 1993). No Brasil temos na cidade de S\u00e3o Paulo, o primeiro relato do uso de \n\ncrack fazendo refer\u00eancia ao ano de 1989 (Dunn et al., 1996).  \n\nEm meados dos anos 90, os usu\u00e1rios de coca\u00edna e crack passaram a ser o \n\ngrupo de usu\u00e1rios de drogas il\u00edcitas que mais procuravam tratamento nos ambulat\u00f3rios \n\n\n\n 16 \n\ne servi\u00e7os de interna\u00e7\u00e3o para depend\u00eancia de subst\u00e2ncias psicoativas (Dunn et al., \n\n1996). Existe atualmente no Brasil uma preocupa\u00e7\u00e3o em estudar o perfil da popula\u00e7\u00e3o \n\nusu\u00e1ria de crack que acessa os servi\u00e7os de sa\u00fade (Ferreira Filho et al., 2003). \n\nEstudos que se direcionem a esta popula\u00e7\u00e3o s\u00e3o importantes, pois se observa \n\no aumento da procura por tratamento dos usu\u00e1rios de crack em suas diversas \n\nmodalidades, inclusive interna\u00e7\u00e3o para desintoxica\u00e7\u00e3o dessa subst\u00e2ncia (Ferri, 1997 et \n\nal.; Parry et al.; Schifano et al., 2008; Borini et al., 2003). \n\nO crack apresenta efeitos como: excita\u00e7\u00e3o, hiperatividade, ins\u00f4nia, muita perda \n\nde peso, cansa\u00e7o, intensa depress\u00e3o, irritabilidade, comportamento violento, tremores, \n\natitudes bizarras, paran\u00f3ia, alucina\u00e7\u00f5es e del\u00edrios e com o uso continuo perda do \n\ninteresse sexual. Cabe ressaltar outros efeitos, como por exemplo, \u201cvis\u00e3o borrada\u201d, dor \n\nprecordial, hipertens\u00e3o, taquicardia, contra\u00e7\u00f5es musculares, rabdomi\u00f3lise, convuls\u00f5es \n\ne at\u00e9 coma e morte (CEBRID, 2009). Em compara\u00e7\u00e3o \u00e0 coca\u00edna, os sinais e sintomas \n\ncausados pelo crack s\u00e3o mais intensos e de curta dura\u00e7\u00e3o (Hartnoll et al., 1987; Jaffe, \n\n1990). \n\nNo Brasil, em fun\u00e7\u00e3o dos in\u00fameros pontos de distribui\u00e7\u00e3o e venda de crack, \n\nsua composi\u00e7\u00e3o qu\u00edmica exata ainda \u00e9 desconhecida, de tal forma que intera\u00e7\u00f5es \n\nimprevis\u00edveis podem colocar a vida do usu\u00e1rio em risco, o que o torna um problema de \n\nsa\u00fade p\u00fablica relevante (Oliveira et al., 2008). O in\u00edcio precoce de uso de qualquer \n\nsubst\u00e2ncia e, em particular, do crack, est\u00e3o relacionados com pior progn\u00f3stico em \n\ntratamento ambulatorial para pacientes na adolesc\u00eancia (Scivoletto, 1998). \n\nEstudos realizados no estado do Rio Grande do Sul demonstram que 80% dos \n\nusu\u00e1rios de crack relataram in\u00edcio do uso da subst\u00e2ncia entre 16 e 26 anos, sugerindo \n\n\n\n 17 \n\na necessidade de abordagem do problema desde a adolesc\u00eancia (Guimaraes et al., \n\n2008). \n\nA magnitude de viol\u00eancia homicida atinge com maior incid\u00eancia a faixa et\u00e1ria \n\nentre 15 e 24 anos e avan\u00e7a nas regi\u00f5es metropolitanas como a de Porto Alegre (RS), \n\nonde observa-se que, tanto adolescentes, quanto adultos jovens representam uma \n\npopula\u00e7\u00e3o exposta ao risco de morte por homic\u00eddios, pois o uso do crack levou a \n\nroubos, atos de viol\u00eancia e ao endividamento dos usu\u00e1rios com os traficantes \n\n(CHESNAIS, 1999). No Brasil, a despeito de todos os esfor\u00e7os empregados para o seu \n\ncontrole, no per\u00edodo de 2001 a 2005, ocorreu um aumento do uso de crack pela \n\npopula\u00e7\u00e3o geral (CEBRID, 2007), especialmente nas regi\u00f5es Sudeste e Sul, com \n\nexpressivo aumento na cidade de Porto Alegre (Inciardi et al., 2009). \n\n2  Dano de DNA \n\nUm estudo investigativo dos poss\u00edveis efeitos t\u00f3xicos da coca\u00edna e crack, sobre \n\no DNA contido no macron\u00facleo do protozo\u00e1rio Tetrahymena pyriformis, mostra que \n\ntanto a coca\u00edna, quanto o crack, afetam significativamente o conte\u00fado de DNA, quando \n\ncomparados as culturas controle. E sugerem, pelo resultado observado, que o crack \u00e9 \n\nmuito mais potente e r\u00e1pido na a\u00e7\u00e3o, do que a coca\u00edna (Stefanidou et al., 2001). Neste \n\nmesmo estudo foi observada a supress\u00e3o da fagocitose no protozo\u00e1rio, \n\ncorrelacionando com outros achados em que a coca\u00edna altera a fun\u00e7\u00e3o das c\u00e9lulas \n\nnatural killer, c\u00e9lulas T e neutr\u00f3filos, e inibe a atividade fagoc\u00edtica de macr\u00f3fagos. Este \n\nefeito supressivo pode contribuir para o comprometimento da imunidade de t\u00f3xico-\n\ndependentes (Pirozhkov et al., 1992; Ou et al, 1989). \n\n\n\n 18 \n\nCorrelacionando o dano de DNA com outras drogadi\u00e7\u00f5es, h\u00e1 na literatura \n\ntrabalhos que relatam um aumento significativo no dano oxidativo ao DNA em \n\nleuc\u00f3citos de indiv\u00edduos expostos \u00e0 fuma\u00e7a ambiental do tabaco e uma correla\u00e7\u00e3o \n\nentre o dano de DNA e da exposi\u00e7\u00e3o ao tabaco, medido pelos n\u00edveis de cotinina no \n\nplasma (Howard et al., 1998; Lodovici et al., 2005). Pesquisas de micron\u00facleos na \n\nmucosa esof\u00e1gica de fumantes e ex-fumantes comparado com grupos controles \n\nmostraram que a freq\u00fc\u00eancia de micron\u00facleos foi significativamente maior entre \n\nfumantes e ex-fumantes (Dietz et al., 2000). \n\nO potencial do fumo de cannabis para causar dano ao DNA foi testado e, na \n\nmaioria dos trabalhos, n\u00e3o foi demonstrado (Wickelgren, 1997; Linszen et al., 1994). \n\nContrapondo a estes, um estudo publicado na Chemical Research in Toxicology \n\nfornece evid\u00eancias para o potencial de danificar o DNA com fumo de cannabis e sugere \n\nque o consumo de cigarros de cannabis pode ser prejudicial para a sa\u00fade humana com \n\na possibilidade de iniciar o desenvolvimento de c\u00e2ncer (Singh, 2009). Sherman (1997), \n\nobservou n\u00edveis mais elevados de danos no DNA em forma de rupturas da fita simples, \n\ndetectados em macr\u00f3fagos alveolares humanos obtidos a partir de fumantes de \n\ncannabis, em compara\u00e7\u00e3o aos n\u00e3o-fumantes atrav\u00e9s da an\u00e1lise por fluoresc\u00eancia das \n\nquebras de fitas simples de DNA, conforme descrito por Jevcak  e  Bimboim (1993)  \n\n \n\n \n\n \n\n \n\n \n\n\n\n 19 \n\n2.1 T\u00e9cnicas para Avalia\u00e7\u00e3o de dano de DNA  \n\n2.1.1 Ensaio Cometa \n\nO teste Cometa ou SCGE (Single Cell Gel Eletrophoresis Assay) \u00e9 um teste de \n\ngenotoxicidade capaz de detectar danos no DNA induzidos por agentes alquilantes, \n\nintercalantes e oxidantes, de forma quantitativa. No presente projeto ser\u00e1 utilizada a \n\nvers\u00e3o alcalina, a qual detecta quebras de fita \u00fanica e dupla, s\u00edtios alcali-l\u00e1beis, e \n\ncrosslinks. Trata-se de uma metodologia simples, barata, r\u00e1pida e que permite a \n\navalia\u00e7\u00e3o de um grande n\u00famero de pessoas (Maluf S, Erdtmann B, 2003). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nFigura 1: ilustra\u00e7\u00e3o das etapas da t\u00e9cnica do cometa (adaptado de Speit, \n\nexposi\u00e7\u00e3o oral, 1998 apud Palazzo, 2010). \n\n\n\n 20 \n\nAtrav\u00e9s dessa t\u00e9cnica, o dano de DNA \u00e9 visualizado individualmente na c\u00e9lula \n\nsob a forma de um aumento na migra\u00e7\u00e3o de material gen\u00e9tico a partir do n\u00facleo \n\n(\u201ccauda\u201d do cometa). O mecanismo da t\u00e9cnica relaciona-se com a organiza\u00e7\u00e3o super-\n\nhelicoidal do DNA, a qual se torna relaxada em fun\u00e7\u00e3o de processos de quebras, \n\npodendo formar estruturas alongadas a partir da eletroforese (Maluf 2004). \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n2.1.2 Teste de Micron\u00facleo \n\nO teste de micron\u00facleos (MN), ou cytokinesis-blocked micronucleus (CBMN) foi \n\ndescrito em medula \u00f3ssea de camundongo, em 1973, por Heddle. Atrav\u00e9s dele \n\ndetectam-se agentes genot\u00f3xicos clastog\u00eanicos e interferentes da forma\u00e7\u00e3o do fuso \n\nmit\u00f3tico, afetando a distribui\u00e7\u00e3o eq\u00fcitativa dos cromossomos na divis\u00e3o celular. O \n\nensaio serve como primeiro passo no estudo de compostos mutag\u00eanicos tendo a \n\nvantagem de ser mais r\u00e1pido do que a an\u00e1lise de quebras cromoss\u00f4micas \n\n(clastog\u00eanese), sendo mais eficiente para detectar a perda de cromossomos inteiros \n\n(aneug\u00eanese) (Heddle 1973). \n\nFigura 2: linf\u00f3citos processados pela t\u00e9cnica do cometa. (A) classe 0, (B) classe 1, (C) \n\nclasse 2, (D) classe 3, (E) classe 4 (Palazzo, 2010). \n\nA B C \n\nD E \n\n\n\n 21 \n\nA freq\u00fc\u00eancia de MN em linf\u00f3citos do sangue perif\u00e9rico humano foi estudada por \n\nCauntryman e Heddle (1976), mostrando a possibilidade de se medir o dano \n\ncromoss\u00f4mico atrav\u00e9s de um tecido de mais f\u00e1cil acesso, j\u00e1 que, originalmente, a \n\nt\u00e9cnica de MN tinha sido descrita apenas para eritr\u00f3citos de medula \u00f3ssea, em 1975 \n\npor Schmid. A dificuldade dessa t\u00e9cnica era distinguir as c\u00e9lulas que, em cultura, \n\nhaviam passado por um ciclo de divis\u00e3o, daquelas que n\u00e3o haviam se dividido (Schmid \n\n1975; Countryman and Heddle 1976). \n\nFenech e Morley, em 1985, utilizaram citocalasina B para bloquear a citocinese \n\ncelular. Desta maneira, apenas as c\u00e9lulas que passam por um ciclo de divis\u00e3o nuclear \n\n(c\u00e9lulas binucleadas) s\u00e3o consideradas na an\u00e1lise de freq\u00fc\u00eancia de MN (Fenech and \n\nMorley 1985). \n\nOs linf\u00f3citos T analisados pelo teste s\u00e3o c\u00e9lulas que circulam por diferentes \n\n\u00f3rg\u00e3os antes de retornar ao sangue perif\u00e9rico. Os linf\u00f3citos podem circular por anos e \n\nat\u00e9 mesmo d\u00e9cadas, acumulando muta\u00e7\u00f5es no seu DNA, produzidas pela sua \n\nexposi\u00e7\u00e3o durante a sua exist\u00eancia (Carrano and Natarajan 1988). \n\nNa an\u00e1lise das c\u00e9lulas binucleadas, podemos encontrar tr\u00eas altera\u00e7\u00f5es \n\ndistintas. A primeira, como j\u00e1 mencionada, equivale aos MN, os quais correspondem a \n\nfragmentos ac\u00eantricos ou cromossomos inteiros que n\u00e3o atingiram o fuso mit\u00f3tico \n\ndurante a divis\u00e3o celular e acabaram expulsos do n\u00facleo (Tucker and Preston 1996). \n\nAs pontes nucleoplasm\u00e1ticas (NPB \u2013 nucleoplasmic bridges), por sua vez, ocorrem \n\nquando os centr\u00f4meros de cromossomos dic\u00eantricos s\u00e3o transferidos para p\u00f3los \n\nopostos da c\u00e9lula na an\u00e1fase. A an\u00e1lise de NB pode fornecer informa\u00e7\u00f5es sobre o tipo \n\nde muta\u00e7\u00e3o envolvida (clastog\u00eanese ou aneug\u00eanese), al\u00e9m de prover a medida de \n\nrearranjos cromoss\u00f4micos (Umegaki and Fenech 2000). Por \u00faltimo, os \u201cbuds\u201d \n\n\n\n 22 \n\nnucleares, correspondem a amplifica\u00e7\u00f5es de DNA encontradas na periferia nuclear \n\n(Fenech and Crott 2002). \n\n \n\n \n\n \n\n \n\nFigura 3: linf\u00f3citos processados pela t\u00e9cnica de micron\u00facleos. (A) linf\u00f3cito binucleado normal, \n\n(B) linf\u00f3cito binucleado com micron\u00facleo, (C) linf\u00f3cito binucleado com ponte nucleoplasm\u00e1tica, \n\n(D) linf\u00f3cito binucleado com BUD (Palazzo, 2010). \n\nA B C D \n\n\n\n 23 \n\n4 OBJETIVOS  \n\n4.1 Objetivo Prim\u00e1rio \n\nAvaliar os \u00edndices de dano de DNA, atrav\u00e9s das T\u00e9cnicas de Micron\u00facleos e do \n\nEnsaio Cometa em usu\u00e1rios ativos de crack em v\u00e1rios momentos a partir da interna\u00e7\u00e3o \n\nem uma cl\u00ednica de reabilita\u00e7\u00e3o e em um grupo controle. \n\n4.2 Objetivos Secund\u00e1rios \n\n1-    Comparar a freq\u00fc\u00eancia de micron\u00facleos, pontes nucleoplasm\u00e1ticas e \u201cbuds\u201d \n\nnucleares em usu\u00e1rios ativos de crack no momento da interna\u00e7\u00e3o em uma cl\u00ednica de \n\nreabilita\u00e7\u00e3o com um grupo controle. \n\n2-    Comparar os \u00edndices de dano de DNA, medidos atrav\u00e9s da T\u00e9cnica do Cometa em \n\nusu\u00e1rios ativos de crack no momento da interna\u00e7\u00e3o em uma cl\u00ednica de reabilita\u00e7\u00e3o com \n\num grupo controle. \n\n3-    Avaliar o efeito do programa de reabilita\u00e7\u00e3o atrav\u00e9s da an\u00e1lise dos \u00edndices de dano \n\nde DNA no momento da interna\u00e7\u00e3o e no final do tratamento, utilizando-se as t\u00e9cnicas \n\nde Micron\u00facleos e Cometa, em usu\u00e1rios ativos de crack, rec\u00e9m internados em uma \n\ncl\u00ednica para reabilita\u00e7\u00e3o. \n\n4-    Avaliar o efeito da a\u00e7\u00e3o do sistema de reparo de DNA, ap\u00f3s a interna\u00e7\u00e3o na cl\u00ednica \n\nde reabilita\u00e7\u00e3o, atrav\u00e9s da an\u00e1lise dos \u00edndices de dano de DNA do Ensaio Cometa, no \n\nmomento da interna\u00e7\u00e3o, 48 horas depois de encerrar o uso da droga e no final do \n\ntratamento.  \n\n5-    Correlacionar cada um dos marcadores de dano de DNA entre eles e com outros \n\nfatores, como idade, consumo de chimarr\u00e3o, tabagismo, consumo de \u00e1lcool, e de \n\noutras drogas il\u00edcitas, assim como o tempo de consumo destas subst\u00e2ncias. \n\n\n\n 24 \n\n5. REFER\u00caNCIAS BIBLIOGR\u00c1FICAS  \n\nBenowitz NL (1992), How toxic is cocaine? In: Ciba Foundation. Cocaine: scientific and \n\nsocial dimensions. Chichester: John Wiley &amp; Sons. Ciba Found Symp. 166:125-43; \n\ndiscussion 143-8. \n\nBorini P, Guimar\u00e3es RC and Borini SB (2003). Usu\u00e1rios de drogas il\u00edcitas internados \n\nem hospital psiqui\u00e1trico: padr\u00f5es de uso e aspectos demogr\u00e1ficos e epidemiol\u00f3gicos. J \n\nBras Psiquiatr. 52(3):171-9. \n\nCarrano AV, Natarajan AT (1998). International Comission for Protection Against \n\nEnvironmental Mutagens and Carcinogens ICPEMC publication n. 14. Considerations \n\nfor population monitoring using cytogenetic techniques. Mutation Research 204(3):379-\n\n406. \n\nCauntryman, PJ.; heddle, JA (1976). The production of micronuclei from chromosome \n\naberration in irradiated cultures of human lymphocytes. Mutation Research. 67:321-332. \n\nCEBRID (2009). Centro Brasileiro de Informa\u00e7\u00f5es Sobre Drogas Psicotr\u00f3picas \n\nDepartamento de Psicobiologia \u2013 UNIFESP.  Boletim Cebrid. N\u00famero 61 \n\nJaneiro/Fevereiro/Mar\u00e7o. \n\nCEBRID (2007). II Levantamento domiciliar sobre o uso de drogas psicotr\u00f3picas no \n\nBrasil: estudo envolvendo as 108 maiores cidades do pa\u00eds. S\u00e3o Paulo: Cebrid \u2013 Centro \n\nBrasileiro de Informa\u00e7\u00f5es sobre Drogas Psicotr\u00f3picas e Unifesp \u2013 Universidade Federal \n\nde S\u00e3o Paulo. \n\nChesnais JC (1999). A viol\u00eancia no Brasil: causas e recomenda\u00e7\u00f5es pol\u00edticas para a \n\nsua preven\u00e7\u00e3o. Ci\u00eanc. Sa\u00fade Coletiva. 4(1):53-69. \n\n\n\n 25 \n\nDas G (1993). Cocaine abuse in North America: a milestone in history. J Clin \n\nPharmacol. 33:296-310. \n\nDunn J, Laranjeira R, Silveira DX, Formigoni MLOS and Ferri CP (1996). Crack \n\ncocaine: an increase in use among patients attending clinics in S\u00e3o Paulo: 1990-1993. \n\nSubst Use Misuse. 31(4): 519-27. \n\nFenech M, Morley AA (1985). Measurement of micronuclei in lymphocytes. Mutation \n\nResearch. 147:29-36. \n\nFenech, M.; Crott, JW (2002). Micronuclei, nucleoplasmic bridges and nuclear buds \n\ninduced in folic acid deficient human lymphocytes \u2013 evidence for brakage \u2013 fusion \u2013 \n\nbridge cycles in the cytokinesis block micronucleus assay. Mutation Research. 504:131-\n\n136. \n\nFerreira Filho OF, Turchi MD, Laranjeira R and Castelo A (2003). Perfil \n\nsociodemogr\u00e1fico e padr\u00f5es de uso entre dependentes de coca\u00edna hospitalizados. Rev. \n\nSa\u00fade Publica. 37(6):751-9. \n\nFerri CP, Laranjeira RR, Da Silveira DX, Dunn J and Formigoni MLOS (1997). Aumento \n\nda procura de tratamento por usu\u00e1rios de crack em dois ambulat\u00f3rios na cidade de S\u00e3o \n\nPaulo, nos anos de 1990 a 1993. Rev Ass Med Bras. 43(1):25-8. \n\nGarcia O, Mandina T, Lamadrid AL, Diaz A, Remigio A, Gonzalez Y  et al (2004). \n\nSensitivity and variability of visual scoring in the comet assay. Results of an inter-\n\nlaboratory scoring exercise with the use of silver staining. Mutat Res. 556:25-34. \n\nGuimaraes CF  et al. (2008) . Perfil do usu\u00e1rio de crack e fatores relacionados \u00e0 \n\ncriminalidade em unidade de interna\u00e7\u00e3o para desintoxica\u00e7\u00e3o no Hospital Psiqui\u00e1trico \n\n\n\n 26 \n\nS\u00e3o Pedro de Porto Alegre (RS). Rev. psiquiatr. Rio Gd. Sul, Porto Alegre,  v. 30,  n. \n\n2, ago.  \n\nGuindalini C. et al. (2006) Concurrent crack and powder cocaine users from S\u00e3o Paulo: \n\ndo they represent a different group? BMC Public Health. 6:10. \n\nHartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, \n\nSmith A, Speit G, Thybaud V and Tice RR (2003). 4th International Comet Assay \n\nWorkshop. Recommendations for conducting the in vivo alkaline Comet assay. \n\nMutagenesis. 18:45-51. \n\nHartnoll R, Daviaud E and Power R (1987). \u201cDrug Use and Misuse: A Reader.\u201d Ed. by \n\nHeller T, Gott M e Jaffery C (1987). Wiley And Sons, Ltd.; Chichester, p. 13-18. \n\nHeddle, JA (1973). A rapid in vivo test for chromosomal damage. Mutation Research. \n\n18: 187\u2013190. \n\nHoward DJ, Ota RB, Briggs LA, Hampton M and Pritsos CA (1998). Oxidative stress \n\ninduced by environmental tobacco smoke in the workplace is mitigated by antioxidant \n\nsupplementation. Cancer Epidemiol. Biomarkers Prev. 7:981\u2013988.  \n\nInciardi JA, Surratt HL, Pechansky F, Kessler F, Von Diemen L and Da Silva EM et al \n\n(2006). Changing patterns of cocaine use and HIV risks in the south of Brazil. J. \n\nPsychoactive Drugs. 38(3):305-10. \n\nJaffe JH (1990). \u201cGoodman and Gilman\u2019s the Pharmacological Basis of Therapeutics, \n\n8th edn,\u201d New York, Pergamon Press. p. 539-545. \n\nJonnes J (1996). High on cocaine. In: Jonnes J. Hep-cats, narcs and pipe dreams \u2013 a \n\nhistory of America\u2019s romance with illegal drugs. New York: Scribner. \n\n\n\n 27 \n\nKessler F and Pechansky F (2008). Uma vis\u00e3o psiqui\u00e1trica sobre o fen\u00f4meno do crack \n\nna atualidade. Rev. psiquiatr. Rio Gd. Sul,  Porto Alegre,  v. 30,  n. 2, Ago..  \n\nLinszen DH, Dingemans PM and Lenior ME (1994). Cannabis abuse and the course of \n\nrecent-onset schizophrenic disorders. Arch. Gen. Psychiatry 51: 273\u2013279. \n\nLodovici M, Caldini S, Luceri C, Bambi F, Boddi V and Dolara P (2005). Active and \n\npassive smoking and lifestyle determinants of 8-oxo-7,8-dihydro-2?-deoxyguanosine \n\nlevels in human leukocyte DNA. Cancer Epidemiol. Biomarkers Prev. 14:2975\u20132977. \n\nMaluf SW and Rdtmann B (2000). Follow-up study of the genetic damage in \n\nlymphocytes of pharmacists and nurses handling antineoplastic drugs evaluated by \n\ncytokinesis-block micronuclei analysis and single cell gel electrophoresis assay. \n\nMutation Research. 471:21-27. \n\nMaluf  SW and Erdtmann B (2003). Biomonotoriza\u00e7\u00e3o do dano gen\u00e9tico em humanos \n\nin: Silva J, Erdtmann B and Henriques JAP. Gen\u00e9tica Toxicol\u00f3gica. 1ed. Porto Alegre: \n\nAlcance. \n\nMoller P, Knudsen LE, Loft S and Wallin H (2000). The comet assay as a rapid test in \n\nbiomonitoring occupational exposure to DNA-damaging agents and effect of \n\nconfounding factors. Cancer Epidemiol Biomarkers Prev. 9:1005-15. \n\nNadin SB, Vargas-Roig LM and Ciocca DRA (2001). The silver staining method for \n\nsingle-cell gel assay. Journal of Histochemistry and Cytochemistry. 49:1183-1186. \n\nNappo SA, Galdur\u00f3z JC and Noto AR (1994). Uso do \u201ccrack\u201d em S\u00e3o Paulo: fen\u00f4meno \n\nemergente? Rev ABP-APAL. 16 (2): 75-83. \n\nNassif Filho ACN, Bettega SG, Lunedo S, Maestri JE and Gortz F (1999). \n\n\n\n 28 \n\nRepercuss\u00f5es otorrinolaringol\u00f3gicas do abuso de coca\u00edna e/ou crack em dependentes \n\nde drogas. Rev Ass Med Brasil 45(3): 237-41. \n\nOliveira LG and Nappo AS (2008). Crack na cidade de S\u00e3o Paulo: acessibilidade, \n\nestrat\u00e9gias de mercado e formas de uso. Rev. Psiquiatr. Cl\u00edn.,  S\u00e3o Paulo,  v. 35,  n.6. \n\nOu WD, Shen ML and Luo YD (1989). Clinical Immunol. Immunopathol. 52: 305\u2014312. \n\nPalazzo RP. Dano e reparo de dna em indiv\u00edduos com ataxia-telangiectasia e em seus \n\npais heterozigotos. Dez. 2010. 60 fls. Disserta\u00e7\u00e3o (Mestrado) \u2013 Universidade Federal \n\ndo Rio Grande do Sul. Porto Alegre 2010. \n\nParry CDH, Pl\u00fcddemann A and Myers BJ (2007). Cocaine treatment admissions at \n\nthree sentinel sites in South Africa (1997-2006): findings and implications for policy, \n\npractice and research. Subst. Abuse Treat Prev. Policy. 2:37. \n\nPirozhkov SV, Watson RR and Chen GJ (1992). Ethanol enhances immunosuppression \n\ninduced by cocaine. Alcohol. 9:489-494. \n\nRibeiro-Ara\u00fajo M, Laranjeira R and Dunn J (1998). Coca\u00edna: bases biol\u00f3gicas da \n\nadministra\u00e7\u00e3o, abstin\u00eancia e tratamento. J. Bras. Psiquiatria. 47(10): 497-511. \n\nSchifano F and Corkery J (2008). Cocaine/crack cocaine consumption, treatment \n\ndemand, seizures, related offences, prices, average purity levels and deaths in the UK \n\n(1990 - 2004). J Psychopharmacol. 22(1):71-9. \n\nSchmid, W. The micronucleus test. Mutation Research. 31:9-15, 1975.Scivoletto S \n\n(1998). Tratamento psiqui\u00e1trico ambulatorial de adolescentes usu\u00e1rios de drogas; Rev. \n\nPsiq. Clin. 25 (4): 191. \n\nSherman MP, Aeberhard EE, Wong VZ, Simmons MS, Roth MD And Tashkin DP \n\n\n\n 29 \n\n(1997). Effects of smoking marijuana, tobacco or cocaine alone or in combination on \n\nDNA damage in human alveolar macrophages. Life Sci. 56: 2201\u20132207.Sherman MP, \n\nAeberhard EE, Wong VZ, Griscavage JM and  Ignarro LJ (1993)  B&amp;hem.  Biophys.  \n\nRes.  Commun.  U: 1301-1308. \n\nSingh NP, Mccoy MT, Tice RR and Schneider EL (1998). A simple technique for \n\nquantitation of low levels of DNA damage in individual cells. Experimental Cell \n\nResearch. 175:184-191. \n\nSingh R (2009). Evaluation of the DNA Damaging Potential of Cannabis Cigarette \n\nSmoke by the Determination of Acetaldehyde Derived N2-Ethyl-2?-deoxyguanosine \n\nAdducts.  Chem. Res. Toxicol.  22:1181\u20131188. \n\nSmart RG (1988). Crack cocaine use in Canada: A new perspective? American Journal \n\nof Epidemiology 127:1315-1317. \n\nStefanidou M, Chatziioannou A, Livaditou A, Rellaki A,  Alevisopoulos G, Spiliopoulou H \n\nand Koutselinis A (2002). DNA Toxicity of Cocaine Hydrochloride and Cocaine \n\nFreebase by Means of DNA Image Analysis on Tetrahymena pyriformis. Biol Pharm \n\nBull. Mar;25(3):332-4. \n\nStrang J, Griffiths P and Gossop M (1990). Crack and cocaine use in south London \n\ndrug addicts: 1987-1990. British Journal of Addiction. 85:193-196. \n\nTice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, \n\nRojas E, Ryu JC and Sasaki YF (2000) Single cell gel/comet assay: guidelines for in \n\nvitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis. \n\n35:206-221. \n\n\n\n 30 \n\nTucker JD, preston RJ (1996). Chromossome aberrations, micronuclei, aneuploidy, \n\nsister chromatid exchanges, and cancer risck assessment. Mutation Research. 365(1-\n\n3):147-519. \n\nUmegaki  K, fenech M (2000). Cytokinesis-block micronucleus assay in WIL2-NS cells: \n\na sensitive system to detect chromosome damage induced by reactive oxygen species \n\nand activated human neutrophils. Mutagenesis 15(3):261-269. \n\nWashton AM, Gold MS and Pottash AC (1986). Crack: Early report on a new drug \n\nepidemic. Postgrad Med. 80: 52-58. \n\nWickelgren I (1997). Marijuana: Harder than thought. Science. 276:1967\u20131968. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 31 \n\n8. MANUSCRITO 1 \u2013 VERS\u00c3O PRELIMINAR  \n\n(ser\u00e1 submetido ao peri\u00f3dico Toxicological Sciences) \n\n \n\nDNA DAMAGE MARKERS IN MALE USERS OF CRACK COCAINE: IMPACT OF A \n\nREHABILITATION PROGRAM \n\n \n\nThiago Aley Brites de Freitas\na,b\n\n, Roberta Passos Palazzo\nb\n, Fabiana Michelsen de \n\nAndrade\nc\n, C\u00e9sar Luis Reichert\n\nc\n, Fl\u00e1vio Pechansky\n\na,b\n, F\u00e9lix Kessler\n\nb\n, Gisele Gomes de \n\nAndrade\nb\n, Sandra Leistner-Segal\n\na,b\n, Sharbel Weidner Maluf\n\nb*\n.\n \n\n \n\na\n Post-Graduate Program in Medicine: Medical Sciences, Universidade Federal do Rio \n\nGrande do Sul (UFRGS), Av. Bento Gon\u00e7alves, 9500 Porto Alegre, RS, Brazil \n\nb\n Medical Genetics Service, HCPA, Rua Ramiro Barcelos, CEP 90035-903, 2350 Porto \n\nAlegre, RS, Brazil\n \n\nC\n Health Science Institute, Feevale University, RS 239, CEP 93352-000, 2755 Novo \n\nHamburgo, RS, Brazil \n\n \n\nCorresponding author:  \n\nSandra Leistner-Segal  \n\nMedical Genetics Service, Hospital de Cl\u00ednicas de Porto Alegre  \n\nRua Ramiro Barcelos 2350, CEP 90035-903  \n\nPorto Alegre, RS, Brazil  \n\nE-mail: ssegal@hcpa.ufrgs.br  \n\nPhone number: 51-33598011  \n\nFax: 51-33598010 \n\n \n\n\n\n 32 \n\nABSTRACT \n\nCrack is a by-product of cocaine that, among many effects, can cause \n\nhypertension, tachycardia, muscle twitching, convulsions and even coma and death. In \n\nthis study, 31 active users of crack cocaine recently admitted for treatment at a drug \n\nrehabilitation centre and 40 control subjects were evaluated. DNA damage was \n\nmeasured in peripheral blood using the comet assay on three occasions: at admission, \n\n48 hours later and at the end of treatment. For the micronucleus (MN) technique, tests \n\nwere performed only at admission and at the end of treatment. Comparison between \n\ncontrols and crack cocaine users showed significant differences in the rates of DNA \n\ndamage (P = 0.037), the frequency of MN (p&lt;0.001) and nuclear buds (NBUDs) (p \n\n<0.001) but not in the frequency of nucleoplasmic bridges (NPBs) (P = 0.089). Rates of \n\nDNA damage quantified with the comet assay at all three time points revealed \n\nstatistically significant values only after the end of treatment (P&lt;0.001), which may \n\nindicate both effective action of the repair system and, as far as possible, elimination of \n\ndamaged cells. The frequency of MN and NPBs calculated during the first assay did not \n\ndiffer from frequencies obtained after treatment, indicating that the detoxification period \n\nwas not long enough to decrease the frequency of already established mutations. The \n\nresults of this study reveal the genotoxic and mutagenic effects of crack cocaine use \n\nand pave the way for further research to investigate cellular responses and the possible \n\nconsequences of DNA damage, such as induction of irreversible neurological disease \n\nand neoplasms. \n\n \n\nKEYWORDS: Crack cocaine, drug rehabilitation, DNA damage, comet assay, CBMN. \n\n \n\n\n\n 33 \n\nINTRODUCTION \n\nCocaine is a central nervous system stimulant extracted from the leaves of \n\nErythroxylum coca (Ribeiro-Ara\u00fajo et al.,1998 apud Duailibi et al., 2008).  Crack \n\ncocaine, or simply crack, is a by-product resulting from the addition of sodium \n\nbicarbonate to cocaine base paste. Crack cocaine is sold in the form of small, porous \n\nrocks (Nassif Filho, et al., 1999), and its effects include euphoria, hyperactivity, \n\ninsomnia, marked weight loss, fatigue, profound depression, irritability, violent \n\nbehaviour, tremors, bizarre actions, paranoia, hallucinations, delirium and, with \n\ncontinued use, loss of sex drive. Further effects include blurred vision, precordial pain, \n\nhypertension, tachycardia, muscle twitching, rhabdomyolysis, convulsions, and even \n\ncoma and death (Cebrid, 2009). The effects of crack are more intense and shorter in \n\nduration than those of cocaine (Hartnoll et al., 1987; Jaffe, 1980). \n\nAn experimental study on the potential toxic effects of cocaine hydrochloride \n\nand freebase cocaine (crack) on macronucleus DNA in the protozoan Tetrahymena \n\npyriformis showed that both forms of cocaine have a significant effect on DNA content, \n\nwith the action of crack being much more potent and rapid than that of cocaine \n\nhydrochloride (Stefanidou, 2001). Very few studies have assessed the potential effects \n\nof crack cocaine at the cellular level. \n\nIn the present study, we assessed genome instability by means of the comet \n\nassay and the cytokinesis-block micronucleus technique (CBMN) in crack cocaine users \n\nat the time of admission to a rehabilitation clinic and in healthy, non-user controls. This \n\ninitial assessment was followed by evaluation during and at the end of treatment to \n\ninvestigate the mechanisms of action and potential consequences of crack cocaine use, \n\nas well as the frequency of several forms of DNA damage after cessation of crack use. \n\n\n\n 34 \n\nMATERIALS AND METHODS \n\nPopulation \n\nThe study sample comprised 31 male active users of crack cocaine, between \n\nthe ages of 18 and 45, recently admitted for treatment at the Centro de Reabilita\u00e7\u00e3o \n\npara Dependentes Qu\u00edmicos Marcelo Campos drug rehabilitation centre in S\u00e3o \n\nLeopoldo, state of Rio Grande do Sul, Brazil, and a control group of 49 participants \n\nmatched by age, sex, and habits. Mean age was 26.12 \u00b1 6.19 years in the test group \n\nand 29.91 \u00b1 9.135 in the control group. Table 1 describes the sample profile. Six \n\nsubjects (19%) were, simultaneously, users of cannabis, cocaine, and tobacco. Most \n\ntobacco users (81%) smoked 15\u201320 cigarettes per day.  \n\nTable 1. Sample profile. \n\n  Crack cocaine users Controls \n\nN*  31  49 \n\nAge 26.13 \u00b1 6.190 29.91 \u00b1  9.135 \n\nCocaine use 10 (32.3%)  0 (0%) \n\nCannabis use 22 (71%)  0 (0%) \n\nTobacco use 21 (67.7%)  14 (28%) \n\nAlcohol intake 19 (61.29 %) 22 (44.9%) \n\nIlex paraguariensis \n\ninfusion \n\n13 (41,94%) 31 (63,26) \n\n*All subjects (test and control) were male as crack consumption is more prevalent \n\namongst this gender.  \n\n\n\n 35 \n\nOverall, 71% of subjects in the test group were cannabis users. Duration of \n\ncannabis use ranged from 2 to 20 years. Non-freebase cocaine was used by 32.3% of \n\nsubjects. The longest history of cocaine use was 17 years. \n\nEach participant underwent collection of 4 mL peripheral blood into heparinised \n\ntubes at three points in time: on admission, 48 hours after admission, and at the end of \n\nthe treatment period (21 to 30 days after admission), for assessment of DNA damage \n\nby means of the comet and micronucleus assays. For the first collection, 31 subjects \n\nwere allocated to the comet assay and 29 to the micronucleus assay. For the second \n\ncollection, the number of subjects was 31 users, with no sampling losses, and for the \n\nthird  collection, the number of subjects was 23 for the comet assay and 21 for the \n\nmicronucleus assay. Sampling loss occurred during the micronucleus assay at the first \n\nand third points of collection due to unsatisfactory growth of some cultures. \n\nFurthermore, by the third point of collection, some subjects in the user group had been \n\nreleased from rehabilitation early and others declined collection, which reduced the \n\nsample size for both techniques. Forty volunteers (students from the Federal University \n\nof Rio Grande do Sul) were used as the control group.  Before collection, all subjects \n\nvoluntarily provided written informed consent for participation and were given a copy of \n\nthe consent form, signed by the principal investigator, which contained an overview of \n\nthe study. Subjects were then administered a personal health questionnaire that \n\ncontained items on drug use and exposure to other potentially genotoxic agents. \n\nAll subjects were approached with the aid of a multidisciplinary team of clinic \n\nstaffers, and all underwent psychiatric assessment for evaluation of cognitive functions. \n\nSubjects who were deemed unfit to provide informed consent for study participation \n\nwere excluded. \n\n \n\n\n\n 36 \n\nMicronucleus assay \n\nBlood samples were cultured in 5 mL RPMI 1640 medium supplemented with \n\n20% foetal bovine serum and 0.2% phytohaemagglutinin per 0.5 mL sample. Culture \n\nvials were incubated at 37\u00baC for 44 h, followed by addition of 4.5 g/mL cytochalasin B \n\n(Cyt B, Sigma), using the method described by Fenech and Morley in 1985 and revised \n\nby Fenech and Crott in 2002. \n\nThe cell suspension was fixated in a 3:1 solution of methanol in acetic acid, \n\nafter standing in hypotonic KCl, and pipetted onto clean slides, which were then stained \n\nby the Giemsa method. The frequency of micronuclei (MN), nucleoplasmic bridges \n\n(NPBs), and nuclear buds (NBUDs) was scored in 2000 binucleated lymphocytes per \n\nindividual (Maluf et al., 2009). \n\nComet assay \n\nThe comet assay protocol was as described by Singh et al. (1998). The assay \n\nitself was carried out as described for in vivo samples (Tice et al., 2000, Hartmann et \n\nal., 2003). Blood samples are mixed with low-melting point agarose, spread onto \n\nagarose-precoated slides, gently covered with cover slips and placed in a cold tray. \n\nOnce samples have solidified, cover slips are removed and the slides left to stand in \n\nlysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, pH 10.2, to which 1% Triton X-100 \n\nand 10% DMSO are added) for 1 or 2 days, under refrigeration. Excess fluid is removed \n\nfrom each slide and all slides are placed in an electrophoresis tank, to which a basic \n\nsolution (300 mM NaOH, 1 mM EDTA, pH > 13) is added. Slides are left to stand in this \n\nsolution for 20 min to enable unwinding of DNA and expression of alkali-labile sites and \n\nsingle-strand breaks. Electrophoresis is then run for 20 min at 25 V, 300 mA, and 0.9 \n\nV/cm. Slides are removed from the electrophoresis tank, washed three times in \n\n\n\n 37 \n\nneutralising solution (0.4 M Tris, pH 7.5), rinsed three times with distilled water and left \n\nto dry at room temperature. All procedures subsequent to blood collection are carried \n\nout so as to prevent interference from light. Slides are then fixated and silver-stained as \n\nper Nadin et al. (2001). For assessment of DNA damage, 100 cells per sample are \n\nexamined under light microscopy (x200 magnification). Cells are scored on a scale of 0 \n\n(no migration) to 4 (maximal migration) according to tail intensity (dimensions and \n\nshape). Therefore, the total sum of damage scores for a sample of 100 cells (the \n\ndamage index, or D) ranges from 0 (no migration in any cell) to 400 (maximal migration \n\nin all cells). Patient and control slides are processed and analysed together (Maluf et al, \n\n2007; Bagatini et al 2008). \n\nStatistical analysis \n\nData were analysed in SPSS 18.0.0, using the Generalized Estimating \n\nEquations (GEE) module for comparison between groups and experimental points. The \n\nGEE settings were distribution = binomial, link = probit, and working correlation matrix = \n\nunstructured for the micronucleus assay and distribution = gamma, link = log, and \n\nworking correlation matrix = unstructured for the comet assay. Bonferroni correction \n\nwas employed. The Mann\u2013Whitney U test and Spearman rank correlation were used for \n\ncomparison of simple parameters such as age and duration of substance use. The \n\nsignificance level was set at 5%. \n\n \n\n \n\n \n\n \n\n \n\n\n\n 38 \n\nRESULTS \n\nComparison of comet assay results in the control group and the test group at all \n\nthree points of assessment showed a significant difference in DNA damage index \n\nscores (P=0.037). Individual comparisons between the control group and the test group \n\nat time points 1 and 2 also revealed significant differences (p<0.001, p=0.020), whereas \n\ncomparison between controls and crack cocaine users at time point 3 showed no such \n\ndifferences (p=0.185). Subjects in the test group also had statistically higher \n\nfrequencies of MN (p<0.001) and NBUDs (p<0.001), but not of NPBs, than the control \n\ngroup at time points 1 and 3 (Table 2).  \n\nTable 2: Frequency of micronuclei (MN), nucleoplasmic bridges (NPBs), and nuclear \n\nbuds (NBUDs) and DNA damage scores (comet assay) in samples collected at \n\nadmission (Time point 1), 48h later (Time point 2), and at the end of treatment (Time \n\npoint 3).  \n\n Controls Time point 1 Time point 2 Time point 3 \n\nComet 13.05 \u00b1 11.79 \n\n(N=40) \n\n29.81 \u00b1 19.34 \n\n*p<0.001 \n\n(N=31) \n\n \n\n22.29 \u00b1 19.95   \n\n*p=0.020 \n\n(N=31) \n\n10.39 \u00b1 8.95  \n\n*** p=0.004 \n\n**p<0.001 \n\n(N=23) \n\nMN 2.62 \u00b1 2.26 \n\n(N=29) \n\n7.67 \u00b1 4.92 \n\n*P<0.001 \n\n(N=29) \n\n- 7.90 \u00b1 3.32 \n\n*p<0.001 \n\n(N=21) \n\nNPBs 0.76 \u00b1 1.70 \n\n(N=29) \n\n1.51 \u00b1 1.52 \n\n(N=29) \n\n- 1.95 \u00b1 2.87 \n\n(N=21) \n\nBuds 1.59 \u00b1 1.88 \n\n(N=29) \n\n6.27 \u00b1 4.24 \n\n*p<0.001 \n\n(N=29) \n\n- 16.86 \u00b1 27.56 \n\n**p=0.009 \n\n(N=21) \n\nStatistically significant differences: *versus the control group; **versus time point 1; \n\n***versus time point 2. \n\n\n\n 39 \n\n \n\nThere were significant differences between DNA damage index scores obtained \n\nwith the comet assay at each of the time points of assessment (P<0.001). Individual \n\ncomparisons revealed that the difference was attributable to values at time point 3, as \n\nthere were no significant differences between values at time points 2 and 1 (Table 2, \n\nFigure 1).  \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nThe frequencies of MN and NPBs observed in samples collected at time point 1 \n\n(on admission) were not significantly different from those observed after treatment. A \n\nsignificant increase in the frequency of NBUDs was observed on comparison between \n\nthese two experimental points (Table 2, Figure 2).  \n\nFigure 1. Damage \u00edndex at each of the \n\nthree time points of assessment and \n\ncomparison with the control group. \n\n\n\n 40 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\nComparative analysis of the different comet classes (markers of damage \n\nintensity) observed at the three experiment points revealed a statistically significant \n\ndifference overall (P<0.001). There were significant differences in the three most \n\ncommon classes of DNA damage between time points 1 and 3 (Figure 3). \n\nFigure 2 (C). Distribution of NBUD \n\nvalues at time points 1 and 3 and \n\ncomparison with the control group \n\nLegend \n* Extreme values \u2013 values that lie \nmore than three times the length of \nthe box from the end of the box. \n? Outliers \u2013 values that lie more than \none and a half times the length of the \nbox from the end of the box. \n \n\nFigure 2 (C). Distribution of NBUD \n\nvalues at time points 1 and 3 and \n\ncomparison with the control group \n\nFigure 2 (B). Distribution of NPB \n\nvalues at time points 1 and 3 and \n\ncomparison with the control group. \n\nFigure 2 (C). Distribution of NBUD \n\nvalues at time points 1 and 3 and \n\ncomparison with the control group \n\n\n\n 41 \n\n \n\n \n\nFigure 3: Comparison of the frequency of damaged cells of each comet class between \n\ntime points 1, 2, and 3 (residual analysis: *p<0.05; **p<0.01) \n\n \n\nTests were conducted to assess the correlation between DNA damage markers \n\nand age, duration of crack cocaine use, time elapsed between last use of crack cocaine \n\nand first blood collection, and duration of tobacco use. Furthermore, comparisons were \n\nmade between subjects in the test group who drank and did not drink alcoholic \n\nbeverages, those who used other illicit drugs and those who did not, those who used \n\ncertain medications and those who did not, and those who drank a popular local \n\nbeverage (Ilex paraguariensis infusion) and those who did not. The following \n\nmedications were used during treatment by some patients: Carbamazepine(61,29%), \n\nClonazepan (benzodiazepines) (9,68%), Paracetamol (acetaminophen)  (3,23%), \n\nFluoxetine (16,13%), clorpromazina (41,94%), Diazepam (benzodiazepines)  (16,13%), \n\nGardenal\u00ae (phenobarbital) (3,23%)e lithium carbonate (9,68%). Positive findings are \n\nshown in Table 3.   \n\n0 \n\n2 \n\n4 \n\n6 \n\n8 \n\n10 \n\n12 \n\n14 \n\n16 \n\n%\n c\n\ne\nll\n\ns\n p\n\ne\nr \n\nc\no\n\nm\ne\nt \n\nc\nla\n\ns\ns\n \n\nclass 1 class 2 class 3 class 4 \n\nTime 1 \nTime 2 \nTime 3 \n\np<0.001 ** \n\n** \n\n** \n\n** \n* \n\n* \n\n\n\n 42 \n\n \n\nTable 3. Statistically significant correlations between nuclear changes and other factors \n\nthat might have an impact on DNA damage markers. \n\nCorrelation P N \n\nIlex paraguariensis infusion x \nMN  \n\n(time point 1) \nP=0.045 13 \n\nDuration of tobacco use \n(years) x D (time point 2) \n\nP=0.043 19 \n\nDuration of tobacco use \n(years) x MN (time point 1) \n\nP=0.017 17 \n\nDuration of tobacco use \n(years) x NPBs (time point 3) \n\nP=0.023 13 \n\nDuration of cocaine use x MN \n(time point 3) \n\nP=0.028 9 \n\n \n\n \n\nAnalyses were also carried out to test for correlation between DNA damage \n\ndetected with the comet assay and damage assessed with the micronucleus assay, \n\ntaking into account the case and control samples as a whole. Results are shown in \n\nTable 4. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 43 \n\nTable 4. Correlation between damage markers. \n\n \nD1 D2 D3 MN1 NPB1 BUD1 MN3 NPB3 BUD3 \n\nD1 \n \n\n0.000 0.001 0.628 0.906 0.424 0.245 0.766 0.004 \n\nD2 \n0.672 \n\n \n0.000 0.783 0.478 0.610 0.862 0.135 0.854 \n\n71 \n\nD3 \n0.413 0.492 \n\n \n0.108 0.737 0.279 0.025 0.117 0.005 \n\n63 63 \n\nMN1 \n0.071 0.040 -0.255 \n\n \n0.000 0.000 0.000 0.000 0.000 \n\n49 49 41 \n\nNPB1 \n0.017 -0.104 0.054 0.590 \n\n \n0.003 0.000 0.000 0.015 \n\n49 49 41 58 \n\nBUD1 \n0.117 -0.075 -0.173 0.546 0.379 \n\n \n0.000 0.077 0.000 \n\n49 49 41 58 58 \n\nMN3 \n0.186 0.028 -0.351 0.851 0.585 0.588 \n\n \n0.000 0.000 \n\n41 41 41 49 49 49 \n\nNPB3 \n0.048 -0.238 -0.249 0.597 0.506 0.255 0.485 \n\n \n0.000 \n\n41 41 41 49 49 49 50 \n\nBUD3 \n0.436 0.030 -0.433 0.684 0.345 0.746 0.681 0.508 \n\n \n41 41 41 49 49 49 50 50 \n\n \n\nLegend: The uppermost (yellow) triangle represents p values, and the bottom (blue) \n\ntriangle, correlation and N. D is the damage rate calculated with the comet assay, \n\nfollowed by the point in time at which samples were collected (time point 1, 2, or 3). MN, \n\nNPB, and BUD are changes observed during the micronucleus assay, also followed by \n\nthe point in time at which samples were collected (time point 1 or 3). \n\n \n\nDISCUSSION \n\nMost patients admitted to the clinic where this study was carried out lived in the \n\nmetropolitan region of Porto Alegre, Rio Grande do Sul. Rehabilitation was court-\n\nordered in the majority of cases, and the expected duration of treatment ranged from 21 \n\n\n\n 44 \n\nto 30 days. Concomitant use of other psychoactive substances, particularly cannabis \n\nand tobacco, was common among our subjects.  \n\nThe comet assay technique proved quite sensitive for detection of DNA damage \n\namong crack cocaine users, as shown by the substantial differences between the case \n\n(user) and control groups at all three time points of assessment. If analysis is restricted \n\nto the initial assessment alone (pre-rehabilitation), the difference is even greater, which \n\nhighlights the genotoxic environment in which these individuals were immersed at the \n\ntime of admission to the rehabilitation clinic. Comparison between controls and cases at \n\nthe third time point of assessment showed no significant difference in DNA damage as \n\nassessed by the comet assay, which shows the impact of rehabilitation treatment.  \n\nThe MN technique revealed that, at the time of admission, subjects in the crack \n\ncocaine group had higher frequencies of MN and NBUDs than controls, but no \n\nsignificant difference in the frequency of NPBs. These findings evince the mutagenic \n\nnature of crack cocaine exposure, as an increased frequency of micronuclei is indicative \n\nof genome instability caused by established mutations beyond any possibility of repair \n\n(Kirsch-Volders e Fenech, 2001). The frequency of nucleoplasmic bridges was relatively \n\nvery low in view of the total number of analysed cells. This finding may be related to the \n\nmechanism of NPB formation, which does not include aneugenesis, only clastogenesis \n\n(Fenech, 2000). Another key factor was the low frequency of these anomalies as \n\ncompared with the MN frequencies found, which is usually observed in studies that \n\nemploy these two markers. Perhaps analysis of 1000 binucleated cells is not enough for \n\nassessment of the frequency of nucleoplasmic bridges in chronic exposure studies.   \n\n \n\nThe findings of the comet assay revealed a reduction in reparable damage \n\nduring treatment, but 48 hours was not a sufficiently long period between assessments \n\n\n\n 45 \n\nfor detection of significant differences. A significant difference was, however, detected \n\nbetween samples collected during initial (pre-treatment) assessment and those \n\ncollected at final (post-treatment) assessment. Once again, this revealed an effect of \n\nrehabilitation treatment, which reduced the rates of DNA damage as measured by the \n\ncomet assay. Considering that this assay evaluates reparable DNA damage (Collins, \n\n2004), these findings show that, with the passage of time, crack cocaine users who did \n\nnot have access to the drug experienced a gradual action of their DNA repair systems, \n\nto the point that users and controls were statistically indistinguishable in terms of comet \n\nassay-evaluated DNA damage at the end of the rehabilitation period. Another potential \n\nhypothesis for this decrease in DNA damage levels is apoptotic elimination of cells \n\ndamaged extremely during increased exposure.  \n\nAnalysis of the distribution of DNA damage classes (damage intensity) at the \n\nthree time points of assessment revealed a uniform decline in DNA damage indices \n\nduring rehabilitation of crack cocaine users, as there was a reduction in all damage \n\nclasses, with cells exhibiting class 1 and class 2 damage (minor damage) accounting for \n\nmost DNA damage observed in this sample. \n\nThe frequency of micronuclei and nucleoplasmic bridges did not decrease after \n\ntreatment, and the number of nuclear buds increased substantially. These findings \n\nsuggest that the length of treatment of these crack cocaine users was not enough to \n\neffect a detectable reduction in markers of mutagenicity. Furthermore, we cannot rule \n\nout an influence of the pharmacological treatment to which subjects were exposed at \n\nthe clinic on nuclear bud formation, as this marker is associated with gene amplification \n\ntriggered by cellular toxicity (Fenech, 2002; Fenech et. al., 2011). \n\n\n\n 46 \n\nRegarding factors other than crack cocaine use, duration of tobacco use was \n\nsignificantly correlated with MN and NPB values and the damage index at different \n\npoints of assessment. This finding highlights the impact of tobacco use as a potentiator \n\nof DNA damage, particularly when other genotoxic exposures are present, as a \n\ncorrelation was detected even though our sample did not include any heavy smokers; \n\nmean cigarette intake was relatively low. Toxic compounds are absorbed from \n\ncigarettes in the same manner as from crack cocaine (El-Zein et. al, 2008). \n\nIn our study, the frequency of MN was highest among crack cocaine users who \n\nalso drank mate a beverage made from the leaves of Ilex paraguariensis and widely \n\nconsumed by the general population of the region where samples were collected on a \n\ndaily basis. Alves et al. (2008) found no increase in MN levels in peripheral blood \n\nlymphocytes after in vitro exposure of cell cultures to mate extract. However, the \n\npresence of organophosphates such as phosphamidon in these extracts may have \n\nexerted an additive effect that compounded the mutagenic damage associated with \n\ncrack cocaine use. Phosphamidon caused considerable genetic damage in human \n\nlymphocytes from peripheral blood, in vitro, and in mice bone marrow, in vivo (Patankar \n\nand Vaidya, 1980). \n\nCONCLUSION \n\nThe results of this study reveal the genotoxic and mutagenic effects of crack \n\ncocaine use and pave the way for further research on cellular responses and the \n\npossible consequences of DNA damage, such as induction of irreversible neurological \n\ndisease and neoplasms.  \n\n \n\n \n\n\n\n 47 \n\nFUNDING \n\nThis study was funded by the Brazilian National Council of Technological and \n\nScientific Development (CNPq), the Rio Grande do Sul Research Foundation \n\n(FAPERGS) and the Hospital de Cl\u00ednicas de Porto Alegre Research and Event \n\nIncentive Fund (FIPE/HCPA).  \n\n \n\nREFERENCES \n\n1. Alves R J V, Jotz G P, Amaral V S do, Montes T M H, Sampaio H, Andrade H H  de \n\n(2008). The evaluation of mate\u00b4 (Ilex paraguariensis) genetic toxicity in human \n\nlymphocytes by the cytokinesis-block in the micronucleus assay. Toxicology in Vitro 22: \n\n695\u2013698. \n\n2. Bagatini P, Palazzo R, Rodrigues M, Costa C, Maluf S W (2008). Induction and removal \n\nof DNA damage in blood leukocytes of patients with type 2 diabetes mellitus undergoing \n\nhemodialysis. Mutation Research, 111 - 115. \n\n3. CEBRID (2009). Centro Brasileiro de Informa\u00e7\u00f5es Sobre Drogas Psicotr\u00f3picas \n\nDepartamento de Psicobiologia \u2013 UNIFESP.  Boletim Cebrid. N\u00famero 61 \n\nJaneiro/Fevereiro/Mar\u00e7o. \n\n4. Collins, A R. The Comet Assay for DNA Damage and Repair. Principles, Applications, \n\nand Limitations Mol Biotechnol. 2004 Mar; 26(3):249-61. \n\n5. Duailibi LB, Ribeiro M, Laranjeira R (2008).  Profile of cocaine and crack users in \n\nBrazil. Cadernos de Sa\u00fade P\u00fablica, 24(Suppl. 4), s545-s557. \n\n6. El-Zein R A, Fenech M, Lopez M S, Spitz M R. and Etzel C J (2008). Cancer Epidemiol \n\nBiomarkers Prev. May; 17(5): 1111\u20131119. \n\nhttp://www.ncbi.nlm.nih.gov/pubmed/15004294\n\n\n 48 \n\n7. Fenech M, Kirsch-Volders M, Natarajan A T, Surralles J, Crott J W, Parry J, Norppa H, \n\nEastmond D A, Tucker J D  and Thomas P (2011). Molecular mechanisms of \n\nmicronucleus, nucleoplasmic bridge and nuclear bud formation in mammalian and \n\nhuman cells. Mutagenesis vol. 26 no. 1 pp. 125\u2013132. \n\n8. Fenech, M.; Crott, J. W (2002). Micronuclei, nucleoplasmic bridges and nuclear buds \n\ninduced in folic acid deficient human lymphocytes \u2013 evidence for brakage \u2013 fusion \u2013 \n\nbridge cycles in the cytokinesis block micronucleus assay. Mutation Research 504:131-\n\n136. \n\n9. Fenech M. Biomarkers of genetic damage for cancer epidemiology \n\n(2002). Toxicology. 181 \u2013 2:411\u20136. \n\n10. Fenech, M . The in vitro micronucleus technique. Mutation Research (2000).  455 81\u2013\n\n95. \n\n11. Fenech, M, morley, A. A (1985). Measurement of micronuclei in lymphocytes. Mutation \n\nResearch. 147:29-36. \n\n12. Hartmann A, Agurell E, Beevers C, Brendler-Schwaab S, Burlinson B, Clay P, Collins A, \n\nSmith A, Speit G, Thybaud V and Tice RR (2003). 4th International Comet Assay \n\nWorkshop. Recommendations for conducting the in vivo alkaline Comet assay. \n\nMutagenesis. 18:45-51. \n\n13. Hartnoll R, Daviaud E and Power R (1987). \u201cDrug Use and Misuse: A Reader.\u201d Ed. by \n\nHeller T, Gott M e Jaffery C (1987). Wiley And Sons, Ltd.; Chichester, P. 13-18. \n\n14. Jaffe JH (1990). \u201cGoodman and Gilman\u2019s the Pharmacological Basis of Therapeutics, \n\n8th edn,\u201d New York, Pergamon Press. p. 539-545. \n\n15. Kirsch-Volders M, Fenech M (2001). Inclusion of micronuclei in non-divided \n\nmononuclear lymphocytes and necrosis/apoptosis may provide a more comprehensive \n\n\n\n 49 \n\ncytokinesis block micronucleus assay for biomonitoring purposes; Mutagenesis, \n\n16(1):51-58. \n\n16. Maluf S W, Mergener M, Dalcanale L, Costa C. C, Polo T, Kayser M, Silva L B Da, Pr\u00e1 \n\nD, Teixeira P (2007). DNA damage in peripheral blood of patients with chronic \n\nobstructive pulmonary disease (COPD). Mutation Research, 626, 180 - 184.  \n\n17. Maluf S, Pra D, Friedrisch J, Bittar C, Da Silva M, Henriques J, Silla L (2009). Length of \n\ntreatment and dose as determinants of mutagenicity in sickle cell disease patients \n\ntreated with hydroxyurea. Environmental Toxicology and Pharmacology, 27, p.26 - 29. \n\n18. Nadin SB, Vargas-Roig LM and Ciocca DRA (2001). The silver staining method for \n\nsingle-cell gel assay. Journal of Histochemistry and Cytochemistry. 49:1183-1186. \n\n19. Nassif Filho ACN, Bettega SG, Lunedo S, Maestri JE and Gortz F (1999). \n\nRepercuss\u00f5es otorrinolaringol\u00f3gicas do abuso de coca\u00edna e/ou crack em dependentes \n\nde drogas. Rev Ass Med Brasil 45(3): 237-41. \n\n20. Patankar N, Vaidya VG (1980). Evaluation of genetic toxicity of insecticide \n\nphosphamidon using in vitro &amp; in vivo mammalian test systems. Indian J Exp Biol. \n\nOct;18(10):1145-7. \n\n21. Ribeiro-Ara\u00fajo M, Laranjeira R and Dunn J (1998). Coca\u00edna: bases biol\u00f3gicas da \n\nadministra\u00e7\u00e3o, abstin\u00eancia e tratamento. J. Bras. Psiquiatria. 47(10): 497-511. \n\n22. Singh NP, Mccoy MT, Tice RR and Schneider EL (1998). A simple technique for \n\nquantitation of low levels of DNA damage in individual cells. Experimental Cell \n\nResearch. 175:184-191. \n\n23. Stefanidou M, Chatziioannou A, Livaditou A, Rellaki A,  Alevisopoulos G, Spiliopoulou H \n\nand Koutselinis A (2001). DNA Toxicity of Cocaine Hydrochloride and Cocaine \n\nFreebase by Means of DNA Image Analysis on Tetrahymena pyriformis. Biol Pharm \n\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Patankar%20N%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=7216266\nhttp://www.ncbi.nlm.nih.gov/pubmed?term=Vaidya%20VG%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=7216266\nhttp://www.ncbi.nlm.nih.gov/pubmed/7216266##\nhttp://www.ncbi.nlm.nih.gov/pubmed/11913528\n\n\n 50 \n\nBull. 2002 Mar;25(3):332-4. \n\n24. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, \n\nRojas E, Ryu JC and Sasaki YF (2000) Single cell gel/comet assay: guidelines for in \n\nvitro and in vivo genetic toxicology testing. Environmental and Molecular Mutagenesis. \n\n35:206-221 \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 51 \n\n7. CONSIDERA\u00c7\u00d5ES FINAIS E PERSPECTIVAS \n\n \n\nA maioria dos pacientes da cl\u00ednica eram moradores da regi\u00e3o metropolitana de \n\nPorto Alegre, sendo internados, em sua maioria, por ordem judicial; por esta \n\ndetermina\u00e7\u00e3o, o tempo previsto para tratamento era de 21 a 30 dias. Assim, aqueles \n\nque buscaram aux\u00edlio de forma volunt\u00e1ria foram minoria, apesar dos graves impactos \n\npessoais e sociais impostos pelo crack. \n\nDurante as entrevistas, alguns usu\u00e1rios relataram fazer o uso do \u201cpitico\u201d, que \n\nde acordo com o relatado, seria o cigarro de maconha, com fragmentos da \u201cpedra\u201d do \n\ncrack. Esta \u00e9 uma forma de inicia\u00e7\u00e3o ao crack. H\u00e1, tamb\u00e9m, uma cren\u00e7a de que os \n\nefeitos tranq\u00fcilizadores da maconha equilibrariam os efeitos excitat\u00f3rios do crack, de \n\nforma que esta combina\u00e7\u00e3o de subst\u00e2ncias est\u00e1 se popularizando.  Alguns indiv\u00edduos \n\nrelataram ter maior utiliza\u00e7\u00e3o da droga ap\u00f3s a ingest\u00e3o de bebida alco\u00f3lica. \n\nO uso concomitante de outras subst\u00e2ncias mostrou-se comum, especialmente \n\nmaconha e tabaco.  \n\nEntre os v\u00e1rios ensaios para medir danos ao DNA, a eletroforese alcalina em \n\ngel de c\u00e9lula \u00fanica (ensaio cometa) \u00e9 um m\u00e9todo sens\u00edvel e poderoso para \n\ndetermina\u00e7\u00e3o de quebras na fita do DNA Com a realiza\u00e7\u00e3o do nosso estudo, \n\nprimeiramente, conseguimos verificar com o ensaio CBMN, que MNs s\u00e3o par\u00e2metros \n\n\u00fateis na diferencia\u00e7\u00e3o de usu\u00e1rios e controles quanto a avalia\u00e7\u00e3o de dano celular, \n\nOs dados apresentados atrav\u00e9s do ensaio cometa evidenciam uma redu\u00e7\u00e3o \n\ngradativa do dano repar\u00e1vel \u00e0 medida que os usu\u00e1rios ficavam sem utilizar a droga. \n\nNa terceira coleta obteve-se um (n) menor que as anteriores, em raz\u00e3o da n\u00e3o \n\nader\u00eancia de alguns usu\u00e1rios ao tratamento. \n\n\n\n 52 \n\nO impacto da coca\u00edna, na forma de crack, \u00e9, ainda, imprevis\u00edvel em nossa \n\nsociedade. O consumo tem aumentado, apesar de esfor\u00e7os p\u00fablicos e de organiza\u00e7\u00f5es \n\nprivadas, para conter o avan\u00e7o desta droga. Estudos que busquem evidenciar \n\nposs\u00edveis danos ao DNA de usu\u00e1rios s\u00e3o, ainda, escassos. Atrav\u00e9s deste estudo \n\npretendemos alertar quanto ao potencial danoso do crack. Este estudo est\u00e1 sendo \n\nampliado e ter\u00e1 um segmento com um (n) maior abrangendo o projeto A\u00e7\u00f5es \n\nIntegradas \u2013 SENAD (Secretaria Nacional de Pol\u00edticas sobre Drogas- Minist\u00e9rio da \n\nJusti\u00e7a \u2013 Brasil), onde ser\u00e1 poss\u00edvel realizar uma grande correla\u00e7\u00e3o de vari\u00e1veis com \n\noutros estudos em andamento na mesma popula\u00e7\u00e3o estudada. \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n\n\n 53 \n\n8. ANEXOS  \n\n \n\n8.1 \u2013 TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO (grupo caso) \n\n \n\nVoc\u00ea est\u00e1 sendo convidado(a) para participar, como volunt\u00e1rio, em uma pesquisa. Ap\u00f3s \n\nser esclarecido(a) sobre as informa\u00e7\u00f5es a seguir, no caso de aceitar fazer parte do estudo, por \n\nfavor, assine ao final deste documento. Em caso de recusa voc\u00ea n\u00e3o ser\u00e1 prejudicado(a) de \n\nforma alguma. Em caso de d\u00favida voc\u00ea poder\u00e1 solicitar o auxilio dos pesquisadores para \n\nmaiores informa\u00e7\u00f5es. \n\n A pesquisa em quest\u00e3o inclui usu\u00e1rios de crack e volunt\u00e1rios n\u00e3o usu\u00e1rios. No caso de \n\nvolunt\u00e1rios com idade inferior a 18 anos, o termo tamb\u00e9m poder\u00e1 ser assinado pelo seu \n\nrespectivo(a) respons\u00e1vel. \n\n \n\nProjeto: Avalia\u00e7\u00e3o dos \u00edndices de DNA danificado em usu\u00e1rios de crack \n\n \n\nI - Justificativa e objetivos da pesquisa: \n\nEste estudo consiste em uma avalia\u00e7\u00e3o das altera\u00e7\u00f5es no material gen\u00e9tico ( danos no \n\nDNA) de cada participante. Estas altera\u00e7\u00f5es ocorrem normalmente nas c\u00e9lulas em n\u00edveis \n\nbastante baixos, e s\u00e3o apontadas como respons\u00e1veis, entre outros efeitos, pelos processos de \n\nenvelhecimento. \n\n \n\nII - Procedimentos que ser\u00e3o utilizados: \n\nSer\u00e3o feitas tr\u00eas coletas de 8 ml de sangue: a primeira no inicio do tratamento, a \n\nsegunda dois dias depois e a terceira no final do tratamento, com o prop\u00f3sito de avaliar a \n\nfreq\u00fc\u00eancia de muta\u00e7\u00f5es atrav\u00e9s da t\u00e9cnica de micron\u00facleos (que avalia quebras maiores) e da \n\nt\u00e9cnica do cometa (que acusa altera\u00e7\u00f5es menores no DNA). Al\u00e9m disso, os participantes ser\u00e3o \n\nsubmetidos a um question\u00e1rio de sa\u00fade pessoal (que envolve quest\u00f5es de alimenta\u00e7\u00e3o, \n\nhist\u00f3rico ocupacional e uso de medicamentos, entre outros). Ap\u00f3s a realiza\u00e7\u00e3o do estudo, \n\ntodas as amostras coletadas ser\u00e3o descartadas. \n\n \n\nIII - Benef\u00edcios que se podem obter e procedimentos alternativos que podem ser vantajosos \n\npara os indiv\u00edduos estudados: \n\nA realiza\u00e7\u00e3o deste estudo permitir\u00e1 conhecer se o DNA dos participantes tem mais \n\naltera\u00e7\u00f5es do que a m\u00e9dia da popula\u00e7\u00e3o, podendo servir estes resultados como base para a \n\npreven\u00e7\u00e3o de efeitos danosos sobre a sa\u00fade. \n\n \n\n\n\n 54 \n\nIV \u2013 Riscos: \n\nA realiza\u00e7\u00e3o do estudo n\u00e3o causar\u00e1 nenhum risco de vida aos participantes. Os riscos \n\nser\u00e3o apenas aqueles existentes em uma coleta de sangue comum (hematoma e dor no local \n\nda pun\u00e7\u00e3o). \n\n \n\nPelo presente Consentimento P\u00f3s-Informa\u00e7\u00e3o, declaro que fui informado de forma clara \n\ne detalhada, dos objetivos, da justificativa, dos procedimentos que serei submetido, dos riscos, \n\ndesconfortos e benef\u00edcios do presente Projeto de Pesquisa, assim como dos procedimentos \n\nalternativos aos quais poderia ser submetido.  \n\n \n\nFui igualmente informado:  \n\n- Da garantia de receber resposta a qualquer pergunta ou esclarecimento a qualquer d\u00favida a \n\ncerca dos procedimentos, riscos, benef\u00edcios e outros assuntos relacionados com a pesquisa;  \n\n- Da liberdade de retirar meu consentimento, a qualquer momento, e deixar de participar do \n\nestudo, sem que isto traga preju\u00edzo \u00e0 continua\u00e7\u00e3o do meu cuidado e tratamento;  \n\n- Da seguran\u00e7a de que n\u00e3o serei identificado e que se manter\u00e1 o car\u00e1ter confidencial das \n\ninforma\u00e7\u00f5es relacionadas com a minha privacidade. \n\nO Pesquisador Respons\u00e1vel por este Projeto de Pesquisa \u00e9 Sharbel Weidner Maluf (fone: \n\n33598011). \n\nHospital de Cl\u00ednicas de Porto Alegre \n\nServi\u00e7o de Gen\u00e9tica M\u00e9dica \n\nRua Ramiro Barcelos, 2350 \n\nCEP 90035-903 \u2013 Porto Alegre - RS \n\nData:  ___/___/___. \n\nNome e assinatura do Paciente ou Volunt\u00e1rio: \n\n_______________________________________________________________  \n\nNome e assinatura do Respons\u00e1vel Legal, no caso de participantes com menos de 18 anos: \n\n_______________________________________________________________ \n\nAssinatura do Pesquisador Respons\u00e1vel: \n\nComit\u00ea de \u00c9tica em Pesquisa \u2013 HCPA \n\nTelefone para contato: 33598304 \n\n \n\n\n\n 55 \n\n8.2 \u2013 TERMO DE CONSENTIMENTO LIVRE E ESCLARECIDO (grupo controle) \n\n \n\nVoc\u00ea est\u00e1 sendo convidado(a) para participar, como volunt\u00e1rio, em uma pesquisa. Ap\u00f3s \n\nser esclarecido(a) sobre as informa\u00e7\u00f5es a seguir, no caso de aceitar fazer parte do estudo, por \n\nfavor, assine ao final deste documento. Em caso de recusa voc\u00ea n\u00e3o ser\u00e1 penalizado(a) de \n\nforma alguma. Em caso de d\u00favida voc\u00ea poder\u00e1 solicitar o auxilio dos pesquisadores para \n\nmaiores informa\u00e7\u00f5es. \n\n A pesquisa em quest\u00e3o inclui usu\u00e1rios de crack e volunt\u00e1rios n\u00e3o usu\u00e1rios, que ser\u00e3o os \n\ncontroles para compara\u00e7\u00e3o. No caso de volunt\u00e1rios com idade inferior a 18 anos, o termo \n\ntamb\u00e9m poder\u00e1 ser assinado pelo seu respectivo(a) respons\u00e1vel. \n\n \n\nProjeto: Avalia\u00e7\u00e3o dos \u00edndices de DNA danificado em usu\u00e1rios de crack \n\n \n\nI - Justificativa e objetivos da pesquisa: \n\nEste estudo consiste em uma avalia\u00e7\u00e3o das altera\u00e7\u00f5es no material gen\u00e9tico (DNA) de \n\ncada participante. Estas altera\u00e7\u00f5es ocorrem normalmente nas c\u00e9lulas em n\u00edveis bastante \n\nbaixos, e s\u00e3o apontadas como respons\u00e1veis, entre outros efeitos, pelos processos de \n\nenvelhecimento. \n\n \n\nII - Procedimentos que ser\u00e3o utilizados: \n\nSer\u00e1 feita uma coleta de 5 ml de sangue perif\u00e9rico com o prop\u00f3sito de avaliar a \n\nfreq\u00fc\u00eancia de muta\u00e7\u00f5es atrav\u00e9s da t\u00e9cnica de micron\u00facleos (que avalia quebras \n\ncromoss\u00f4micas e perdas do cromossomo inteiro) e da t\u00e9cnica do \"cometa\" (que acusa \n\naltera\u00e7\u00f5es menores no DNA). Al\u00e9m disso, os participantes ser\u00e3o submetidos a um question\u00e1rio \n\nde sa\u00fade pessoal (que envolve quest\u00f5es de alimenta\u00e7\u00e3o, hist\u00f3rico ocupacional e uso de \n\nmedicamentos, entre outros). Ap\u00f3s a realiza\u00e7\u00e3o do estudo, todas as amostras coletadas ser\u00e3o \n\ndescartadas. \n\n \n\nIII - Benef\u00edcios que se podem obter e procedimentos alternativos que podem ser vantajosos \n\npara os indiv\u00edduos estudados: \n\nA realiza\u00e7\u00e3o deste estudo permitir\u00e1 conhecer se o DNA dos participantes tem mais \n\naltera\u00e7\u00f5es do que a m\u00e9dia da popula\u00e7\u00e3o, podendo servir estes resultados como base para a \n\npreven\u00e7\u00e3o de efeitos danosos sobre a sa\u00fade. \n\nIV \u2013 Riscos: \n\nA realiza\u00e7\u00e3o do estudo n\u00e3o causar\u00e1 nenhum risco de vida aos participantes. Os riscos \n\nser\u00e3o apenas aqueles existentes em uma coleta de sangue comum (hematoma e dor no local \n\nda pun\u00e7\u00e3o). \n\n\n\n 56 \n\n \n\nPelo presente Consentimento P\u00f3s-Informa\u00e7\u00e3o, declaro que fui informado de forma clara \n\ne detalhada, dos objetivos, da justificativa, dos procedimentos que serei submetido, dos riscos, \n\ndesconfortos e benef\u00edcios do presente Projeto de Pesquisa, assim como dos procedimentos \n\nalternativos aos quais poderia ser submetido.  \n\n \n\nFui igualmente informado:  \n\n \n\n- Da garantia de receber resposta a qualquer pergunta ou esclarecimento a qualquer d\u00favida a \n\ncerca dos procedimentos, riscos, benef\u00edcios e outros assuntos relacionados com a pesquisa;  \n\n- Da liberdade de retirar meu consentimento, a qualquer momento, e deixar de participar do \n\nestudo, sem que isto traga preju\u00edzo \u00e0 continua\u00e7\u00e3o do meu cuidado e tratamento;  \n\n- Da seguran\u00e7a de que n\u00e3o serei identificado e que se manter\u00e1 o car\u00e1ter confidencial das \n\ninforma\u00e7\u00f5es relacionadas com a minha privacidade. \n\n \n\nO Pesquisador Respons\u00e1vel por este Projeto de Pesquisa \u00e9 Sharbel Weidner Maluf (fone: \n\n33598011). \n\nHospital de Cl\u00ednicas de Porto Alegre \n\nServi\u00e7o de Gen\u00e9tica M\u00e9dica \n\nRua Ramiro Barcelos, 2350 \n\nCEP 90035-903 \u2013 Porto Alegre - RS \n\n \n\nData:  ___/___/___. \n\n \n\nNome e assinatura do Paciente ou Volunt\u00e1rio: \n\n_______________________________________________________________  \n\nNome e assinatura do Respons\u00e1vel Legal, no caso de participantes com menos de 18 anos: \n\n_______________________________________________________________ \n\nAssinatura do Pesquisador Respons\u00e1vel: \n\nComit\u00ea de \u00c9tica em Pesquisa \u2013 HCPA \n\nTelefone para contato: 33598304 \n\n\n\n 57 \n\n8.3 \u2013  Question\u00e1rio de Sa\u00fade Pessoal \n\n \n\n \n\n \n\n \n\n \n\nEste question\u00e1rio, assim como o estudo a ele relacionado deve ser de seu interesse. A \n\nparticipa\u00e7\u00e3o \u00e9 espont\u00e2nea e constar\u00e1 destas informa\u00e7\u00f5es gerais sobre sa\u00fade e dieta, mais \n\numa coleta de sangue para estudo citogen\u00e9tico. O estudo consiste em uma avalia\u00e7\u00e3o de \n\nmuta\u00e7\u00f5es nos cromossomos de cada participante. Muta\u00e7\u00f5es cromoss\u00f4micas ocorrem \n\nnormalmente nas c\u00e9lulas de todas as pessoas em n\u00edvel bastante baixo, e s\u00e3o apontadas, entre \n\noutros efeitos, nos processos de envelhecimento e c\u00e2ncer. Este estudo poder\u00e1 servir como \n\nsinal de alerta para prevenir e melhorar a qualidade de vida dos participantes.  \n\nLeia e responda cuidadosamente as seguintes quest\u00f5es. A informa\u00e7\u00e3o dada por voc\u00ea \n\nn\u00e3o ser\u00e1 associada com o seu nome, sendo conhecida apenas pelos pesquisadores \n\nassociados a este estudo. As respostas deste question\u00e1rio poder\u00e3o ter influ\u00eancia direta na \n\ninterpreta\u00e7\u00e3o de nossos resultados. Por isso, contamos com sua coopera\u00e7\u00e3o em fornecer \n\ninforma\u00e7\u00f5es corretas. \n\n Obrigado pelo seu interesse. \n\n1. Nome:  \n\nData:      /      / \n\n2. Para ser preenchido pelo pesquisador:     C\u00f3digo n\u00ba: \n\nEsta folha ser\u00e1 destacada das demais do question\u00e1rio e arquivada. Apenas o n\u00famero do \n\nc\u00f3digo ser\u00e1 usado como identifica\u00e7\u00e3o nas pr\u00f3ximas p\u00e1ginas. Se os espa\u00e7os adicionais forem \n\nnecess\u00e1rios para completar uma resposta, por favor, escreva atr\u00e1s da p\u00e1gina e identifique o \n\ncomplemento da resposta com o n\u00famero da quest\u00e3o. \n\n \n\n \n\n \n\n \n\n \n\nQUESTION\u00c1RIO DE SA\u00daDE PESSOAL \n \n\n (De acordo com modelo recomendado por: International Comission for Protection against \n\nEnvironmental Mutagens and Carcinogens (ICPEMC) Mutation Research, 204:379-\n\n406,1988) (Carrano, 1988), adaptado para o estudo. \n\n\n\n 58 \n\nC\u00f3digo n\u00ba:____________ \n\n- Data de hoje: _________________________________________________ \n\n- Qual a sua idade? (em anos)_____________________________________ \n\n- Sexo:   (   ) Masculino (   ) Feminino \n\n- Descrever a rotina di\u00e1ria com possibilidade de exposi\u00e7\u00f5es a agentes mutag\u00eanicos (por \nexemplo, gases t\u00f3xicos, benzeno, chumbo, f\u00e1rmacos, agrot\u00f3xicos, radia\u00e7\u00e3o, etc). Qual foi a \nfreq\u00fc\u00eancia? Qual foi o per\u00edodo? \n____________________________________________________________________________\n____________________________________________________________________________\n____________________________________________________________________________\n____________________________________________________________________________\n____________________________________________________________________________\n____________________________________________________________________________\n_____________________________________________________ \n\nHIST\u00d3RIA DE FUMO \n\nAlguma vez voc\u00ea fumou?     (   )Sim     (   )N\u00e3o \n\nSe n\u00e3o, passe para a quest\u00e3o 6. Se sim, continue: \n\nQuanto tempo voc\u00ea fumou? (em anos) _______________ \n\nVoc\u00ea fuma atualmente?   (   )Sim   (   )N\u00e3o \n\nQuando parou de fumar? (m\u00eas e ano) ____________________________________ \n\nO que voc\u00ea fumava? __________________________________________ \n\nVoc\u00ea fuma cigarros?   (   )Sim   (   )N\u00e3o \n\n              Se sim, quantas carteiras por dia?       (   ) Menos de \u00bd carteira \n\n                                                                             (   ) \u00bd a 1 carteira \n\n                                                                             (   ) Mais de 1 (quantas?______) \n\nVoc\u00ea fuma cigarros com filtro? (   )Sim   (   )N\u00e3o \n\nQual a sua marca usual?____________________________________________ \n\nVoc\u00ea fuma charutos? Quantos por dia?_________________________________ \n\nVoc\u00ea fuma cachimbos? Quantos por dia?_______________________________ \n\n \n\n \n\n \n\n \n\n \n\n\n\n 59 \n\nC\u00f3digo n\u00ba:____________ \n\nMEDICAMENTOS E DOEN\u00c7AS (pode ser pesquisado no prontu\u00e1rio, se for o caso) \n\n- Voc\u00ea tem tomado algum medicamento prescrito pelo m\u00e9dico no \u00faltimo ano? (por exemplo, \ncomprimidos para a press\u00e3o, insulina, tranq\u00fcilizantes, relaxantes musculares, etc.)                                \n(   )Sim   (   )N\u00e3o \n\nSe sim, por favor, indique: \n\nTIPO DE \n\nMEDICAMENTO \n\n \n\nDOSE \n\nQUANTIDADE \n\nPOR DIA \n\nIN\u00cdCIO \n\n(M\u00caS) \nT\u00c9RMINO (M\u00caS) \n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n_______________________________________________________________________ \n\n- Voc\u00ea tem tomado algum medicamento n\u00e3o prescrito por m\u00e9dico  no \u00faltimo ano? (por \nexemplo, aspirina, anti-\u00e1cidos, anti-histaminas, sedativos ou outras drogas)  \n\n(   )Sim   (   )N\u00e3o \n\n    Se sim, por favor, indique \n\nTIPO DE \n\nMEDICAMENTO \n\nDOSE QUANTIDADE \n\nPOR DIA \n\nIN\u00cdCIO \n\n(M\u00caS) \nT\u00c9RMINO (M\u00caS) \n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n_______________________________________________________________________  \n\nVoc\u00ea teve ou tem alguma dessas doen\u00e7as? \n\n(   ) C\u00e2ncer \n\n(   ) Hepatite  \n\n \n\n \n\nSe sim, indique:  \n\n \n\n \n\n \n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n____________________________________________________________________________\n\n________________________________________________________________________ \n\nDOEN\u00c7A PER\u00cdODO TRATAMENTO \n\n(   ) Doen\u00e7a cardiovascular \n\n(   ) Diabete \n\n(   ) Outras doen\u00e7as importantes \n\n\n\n 60 \n\nC\u00f3digo n\u00ba:____________ \n\n-  Voc\u00ea j\u00e1 passou por algum tratamento medicamentoso agressivo? (como quimioter\u00e1picos e \nanti-retrovirais) \n____________________________________________________________________________\n______________________________________________________________________ \n\n-  Voc\u00ea j\u00e1 se submeteu a uma cirurgia? Qual? Quando? \n____________________________________________________________________________\n______________________________________________________________________ \n\nDIETAS (deve refletir apenas os h\u00e1bitos freq\u00fcentes) \n\n17. Voc\u00ea come apenas vegetais?   (   )Sim   (   )N\u00e3o \n\n18. Comente sobre a sua dieta, caso ela tenha algo de especial (por exemplo, dieta \nrica em prote\u00ednas e pobre em carboidratos, etc) \n\n_____________________________________________________________________________________\n_____________________________________________________________________________________\n__________ \n\n19. Voc\u00ea ingere alguma dessas bebidas? Qual a freq\u00fc\u00eancia? \n\n(   ) caf\u00e9  ____________________________________   \n\n(   ) ch\u00e1  _____________________________________ \n\n(   ) chimarr\u00e3o  ________________________________ \n\n \n\n20. Voc\u00ea bebe cerveja?    (   )Sim   (   )N\u00e3o \n\n(   ) 1 \u2013 6 garrafas por semana ou menos \n\n(   ) 7 \u2013 12 garrafas por semana \n\n(   ) Mais de 12 garrafas por semana. Quantas?__________  \n\n \n\n21. Voc\u00ea bebe vinho?   (   )Sim   (   )N\u00e3o \n\n(   ) 1 \u2013 4 copos por semana \n\n(   ) 5 \u2013 8 copos por semana \n\n(   ) 9 \u2013 16 copos por semana \n\n(   ) Mais de 16 copos por semana. Quantos?_____________ \n\n \n\n\n\n 61 \n\n22. Voc\u00ea bebe outras bebidas alco\u00f3licas (excluindo cerveja e vinho)? \n\n   (   ) Sim       (   ) N\u00e3o \n\n Se sim, qual ou quais?____________________________ \n\n \n\nPor favor, indique a sua m\u00e9dia de consumo semanal: \n\n(   ) 1 \u2013 4 copos por semana ou menos \n\n(   ) 5 \u2013 8 copos por semana \n\n(   ) 9 \u2013 16 copos por semana \n\n(   ) Mais de 16 copos por semana. Quantos?____________ \n\n \n\nDROGAS IL\u00cdCITAS \n\n23. Voc\u00ea fuma maconha? \n\n(   ) Sim       (   ) N\u00e3o \n\n Se sim, qual a frequ\u00eancia? ____________________________ \n\n \n\n24. Voc\u00ea cheira coca\u00edna? \n\n(   ) Sim       (   ) N\u00e3o \n\n Se sim, qual a frequ\u00eancia? ____________________________ \n\n \n\n25. Qual \u00e9 a sua frequ\u00eancia de uso do crack? \n\n(   ) 1 \u2013 5 pedras por dia \n\n(   ) 5 \u2013 10 pedras por dia \n\n(   ) 10 \u2013 20 pedras por dia \n\n(   ) 20 ou mais pedras por dia"}]}}}